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WITH A SERIES OF POLYCYCLIC HY-
DROCARBON DERIVATIVES. R. F. NEW-
BOLD, J. AMOS and P. BROOKES, Chemical Car-
cinogenesis Division, Pollards Wood Research
Station, Nightingales Lane, Chalfont St Giles
Bucks.
A series of reactive derivatives of polycyclic
hydrocarbons including the suspected ultimate
carcinogenic form of b0nzo(a)-pyrene, were
examined for cytotoxic andmutagenic properties
usingChinese hamster cells in culture. In view of
the highly variable reactivities of the com-
pounds, mutation frequencies were initially com-
pared in relation to lethality, rather than dose.
In this comparison the compounds formed two
distinct groups viz. those with a low and those
with a high mutagenic efficiency.
To achieve the ideal quantitative comparison,
one example of each group was obtained highly
tritiated, and mutation frequencies were related
to the extent ofhydrocarbon-DNA reaction. The
results of these experiments will be considered
in relation to current theories of hydrocarbon
carcinogenicity.
TEST FOR REPAIR REPLICATION OF
DNA IN VIVO IN LIVER OF ANIMALS
TREATED WITH CARCINOGENS. V. M.
CRADDOCK, MRC Toxicology Unit, Woodman-
sterne Road, Carshalton, Surrey.
Initiation of cancer by chemicals is usually
associated with DNA damage and repair replica-
tion. A few carcinogens were anomalous in that
there was either no evidence for reaction with
DNA (thioacetamide, CC14), thelevel was exceed-
ingly small (ethionine), or there was little evi-
dence for repair replication in the target tissue
(retrorsine, aflatoxin). Unscheduled synthesis
was studied using a zonal technique for separa-
tion of replicating and non-replicating nuclei.
Incorporation of 3H-TdR into replicating nuclei
represented de novo synthesis of DNA, while
HU-resistant incorporation into non-replicating
nuclei represented repair replication (1976,
Biochim. Biophys. Acta, 447, 53). A rapid onset
of repair replication occurred after treatment
with retrorsine or aflatoxin, suggesting repair of
damage caused by rapidly formed metabolites of
the carcinogens. There was delayed repair after
CC14 (possibly repair of DNA damage caused by
nucleases liberated from damaged lysosomes)
and after ethionine (possibly repair of damage
caused by SAE, a metabolite which is slow to
accumulate). No evidence was found for repair
replication after thioacetamide. This compound
may cause restorative hyperplasia of injured
liver rather than hepatocellular carcinoma, in
the animals used. Thus, each ofthe carcinogens
tested caused repair replication, but this was not
necessarily repair of damage caused by reaction
of DNA with a rapidly formed metabolite.
A RADIOIMMUNOASSAY FOR O6-
ALKYL GUANINE DERIVATIVES. S. A.
KYRTOPOULOs and P. F. SWANN, Courtauld
Institute of Biochemistry, The Middlesex Hospital
Medical School.
Among the reactions between carcinogenic
nitroso compounds and the DNA of target
tissues, the alkylation of the 06 position of
guanine is thought to be ofparticular importance
in the induction of cancer. Previous methods for
the estimations of the extent of this reaction
have been very slow and laborious (Lawley
(1976) in Screening Tests in Chemical Carcino-
genesis, IARC Scientific Publications No. 12,
p. 181). We have developed a rapid radioimmu-
noassay for estimating 06-alkylated guanine
derivatives. Rabbit antibodies to 06-methyl-2'-
deoxyguanosine have been used to bind 06-
methyl-[8-3H]-2'-deoxyguanosine. From the
competitive inhibition of this binding by ana-
logous bases and nucleosides, one may estimate
the amounts of these competitors. By this me-
thod, amounts as low as 1 pmol of 06-methyl-2'-
deoxyguanosine, 10 pmol of 06-ethyl-2'-deoxy-
guanosine, 100 pmol of 06-methylguanine and
500 pmol of 06-ethylguanine can be measured.
(A single dose ofdimethylnitrosamine, whichwill
induce kidney tumours in the rat, produces 100
mol of 06-methyl-guanine per 106 mol of gua-
nine, i.e. -100 pmol/mg of DNA.) The useful-
ness and limitations of the method in the study
of nucleic acid alkylation are discussed.
DISTRIBUTION OF 7-METHYLGUA-
NINE IN LIVER CHROMATIN DNA
FROM RATS TREATED WITH N,N-
DI[14C]METHYLNITROSAMINE. A. I.
GALBRAITH and R. F. ITZHAKI, Paterson Labora-
tories, Christie Hospital and Holt Radium
Institute, Manchester.
Investigation into the possible mode of
action of some carcinogenic monofunctional
alkylating agents has failed to show any correla-
tion between the relative amounts of the major
alkylation product 7-alkylguanine in the DNA
of target organs and the carcinogenicity of the
drug. For this reason this product is not con-
sidered to be the critical lesion. However, the
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possibility of non-random distribution of this
alkylation product along the DNA molecule
(e.g. a higher concentration in the unique se-
quences) could provide an alternative explana-
tion. The first such study, on rat liver chromatin
DNA after in vivo administration of dimethyl-
nitrosamine, was made by the separation of
chromatin DNA into poly-L-lysine accessible
and inaccessible zones (Cooper et al., (1975)
Chem. Biol. Interactions, 11, 483). It was shown
that the level of alkylation was lower in the
former regions.
In the present study, chromatin DNA was
prepared from rat livers 3 h after injection of
the hepatocarcinogen N,N-di[14C]methylnitro-
samine, and fractionated into the three kinetic
classes (higher repetitive, middle repetitive and
single-copy sequences) using hydroxyapatite.
The specific activity of both the single- and
double-stranded DNA was measured at various
CoT values. It was found that the radioactivity
was distributed uniformly between the above
classes of chromatin DNA. Since 70% of the
radioactivity is due to 7-methylguanine, it is
most probable that this alkylation product is
distributed uniformly too.
Experiments are now in progress to measure
the 7-methylguanine directly, and to study the
distribution of a minor alkylation product (06-
methylguanine) which is now thought to be
involved in carcinogenesis.
SEX HORMONES AND INTRA-CRANIAL
GLIOMATA. J. W. HOPEWELL, Research
Institute, Churchill Hospital, Oxford.
Intra-cranial tumours of glial origin can be
induced in the rat by the intra-cerebral implant
of 3-4 benzpyrene into the brain so that the
pellet of carcinogen impinges on the subependy-
mal plate. This is a mitotically active layer of
cells found around the lateral wall of the lateral
ventricles.
Deaths from tumour, which occur after a
latent period of 9 months or longer, are more
common in males than females. Castration or
ovariotomy at the time of implantation will sig-
nificantly reduce the number of animals that
develop gliomas. This effect is not corrected by
the exogenous supply of testosterone, a finding
which implicates sex hormone precursors in
glioma induction.
Examination of glioma incidence in man over
the period 1961-70 in data supplied by the Liver-
pool Cancer Registry showed human cerebral
tumours to be more common in males. Further-
more, age-related changes in tumour incidence
could be linked with sex-hormone changes. In
females aged 45 years and over,tumouirincidence
falls relative to that observed in males, where
incidence continues to rise sharply with age. A
peak incidence in males is reached in the 60-65-
year age group and thereafter it declines. These
observations are discussed in the light of the
experimental findings in the rat.
THE INDUCTION OF TUMOURS OF
THE DIGESTIVE TRACT AND OF CER-
TAIN OTHER ORGANS IN RATS GIVEN
T-2 TOXIN, A SECONDARY METABO-
LITE OF FUSARIUM SPOROTRI-
CHIOIDES. R. SCHOENTAL, A. Z. JOFFE and
B. YAGEN, Royal Veterinary College, London and
the Hebrew University, Jerusalem.
Rats were given T-2 toxin (3oc-hydroxy-4/3,
15 - diacetoxy - 80c - (methylbutyryloxy) - 12,13 -
epoxy-A9-trichothecene) which has been isolated
from crude extracts ofF. sporotrichioides by Dr
Yagen, in Jerusalem, in pure crystalline form.
The rats were white, weanlings obtained from
the MRC Laboratory Animals Centre, Carshal-
ton, Surrey. These were given freshly prepared
solutions ofT-2 toxin, by stomach tube (1-4 mg/
kg body weight) and the dosing repeated at
various intervals. Among rats, which survived
longer than 16 months after the first dose, and
5-8 doses of T-2 toxin, chronic and neoplastic
lesions were present, which included: tumours
(benign and malignant) of the pituitary, brain,
pancreas, mammary gland, as well as adenocar-
cinoma of the stomach and duodenum. The im-
plications ofthese results for human health have
to be seriously considered (compare Schoental,
Joffe and Yagen, 1976, Br. J. Cancer, 34, 310).
THE PREDICTIVE CAPACITY OF IN
VITRO DRUG SENSITIVITY TESTS;
STUDIES ON A HUMAN TUMOUR
XENOGRAFT. A. BATEMAN, Institute of
Cancer Research, Sutton, Surrey.
The aim of our present work is the develop-
ment of an in vitro test to measure the chemo-
sensitivity of cancer cells obtained directly from
patients. An assay of clonogenic cells prepared
from fresh biopsies of human tumours has been
developed in our department and we intend to
use it to measure the survival ofthese cells after
incubation with chemotherapeutic agents in
vitro. Since the parameters of drug exposure in
vitro differ from pharmacological conditions, we
report preliminary experiments to test whether
drug toxicity in vitro is a good indicator of in
vivo effect. Cells from a human tumour xenograft
(HX32) were exposed to various concentrations
of a drug, either in vitro or in the host mouse,
and the resultant clonogenic cell survival was
measured. The cytotoxic effect on HX32 cells
was recorded for each of 8 drugs used in vitro at
concerntratioris achieved in patient's plasma.
171B.A.C.R. 19TH ANNUAL GENERAL MEETING
The drugs were then ranked in order of in vitro
toxicity. Similarly, the 8 drugs were ranked
according to toxicity to HX32 tumours in mice
injected with 1OLD doses.
We conclude that in vitro druigsensitivity tests
can be used to predict relative in vivo activity,
if care is taken to use drug concentrations and
exposure times in vitro which reseinble pharmna-
col gical exposures.
ESTABLISHMENT OF PRIMARY HU-
MAN PANCREATIC CARCINOMA IN
CONTINUOUS CULTURE AND IN
IMMUNE-DEPRIVED MICE. A. G. GRANT,
D. DUKE and J. HERMON-TAYLOR, Department
of Surgery, St George's Hospital Medical School
and Cancer Cheemotherapy, ICRF, London.
An epithelioid cell line derived from human
pancreatic exocrine adenocarcinorna has been
grown in culture for one year. The cells have a
doubling time of 48 h and grow to an almost
confluent monolayer, together with a constant
population ofviable "floating" cellsinthegrowth
medium. Evidence of their tumourgenicity is
provided by growth on a fibroblast monolayer
and in soft agar. Progressively growing solid
tumours have been obtained in nude mice
following injection of cells in 6th or 8th passage.
Miouse xenografts have also been established
directly from primary tumour tissue obtained
from two pancreatic cancers, and have been suc-
cessfully passaged in vivo. Each tumour line
exhibits different btut stable growth character-
istics.
An electrophoretic study of the exportable
pancreatic digestive enzymes and selected intra-
cellular enzymes present in these tissues has
shown that neither the cell line, xeniografts, nor
the primary tuinour tissues produce pancreatic
cancer-specific isoenzymes likely to be of clinical
diagnostic use.
THE IMPORTANCE OF SERUM PRO-
TEINS IN HUMAN LYMPHOMAS. J. G.
MCATIE and D. HOLE*, Department of Clinical
Oncology, University of Glasgow and *Cancer
Surveillance Unit, Ruchill Hospital, Glasgow.
One hundred consecutive patients presenting
with a diagnosis oflymphomawerestudied. Each
patient was staged pathologically and treated
conventionally with radiotherapy, chemotherapy
or both according to stage. Forty patients had
Hodgkin's disease and 60 non-Hodgkin's lvm-
phomna. Patients have been followed up from 2
to 7 years. Thirty-two patients have died in that
tine, and they had significatntly lower pretreat-
mnent, values for serum albtmiin, serum immuno-
globtulin M, serum oc2-mnacroglobulin. A 5-,year
actuarial survival for the hypoalbuininaemic
patients is 56% compared to 76% for patients
with normal serum albumin (P=0-01). Hypo-
albuminaemia predisposed to gram-negative in-
fections and episodes of bleeding, but was not
associated with grain-positive infection, viral or
fungal infections. In contrast, abnormally low
levels of IgG, IgM and a2-macroglobulin were
found in the grouip which developed grain-
positive infections. Low albumin was not con-
comnitant with weight loss and was an indepen-
dent variable in prognosis; it was not related to
liver involvement, as only 3100 of the hypo-
albuminaemic group had lymphoina in the liver.
Hypoalbuminaemia was found in all stages of
lymphomas and in all histologies. Repeated
measurement of serum protein including imnmll-
noglobulins was of little value in monitoring
patients' progress, with the exception that in the
group who did not go into remission, the IgM
level fell by a mean of 4500 from pretreatment
values in comparison to 20% fall in the group
which went into remission. There was no change
in O2-macroglobulin levels with time and treat-
mnent, and minimal depression of IgG and IgA.
Serum albuimin rose in patients who weint into
remission and fell in patients who went on to die
ofthe disease. Pretreatment estimation ofserum
albumin, IgM and x2-macroglobulin gives im-
portant prognostic information which identifies
high-risk patients, who might be managed by
intensive support prior to cytoreductive therapy.
PROGNOSTIC VALUE OF SERUM PRO-
TEINS IN LUNG CANCER. C. E. NEWMAN,
C. HI. J. FORD, N. KALSHEKER*, A. R. BRAD-
WELL* and D. BURNETT*, Surgical Immunology
Unit, *Department of Surgery and Imrnuno-




ments and other serum proteins may be usefuil in
monitoring disease status in cancer patients
(Neville and Cooper, 1976, Ann. Clin. Biochem.,
13, 280). Serial measurements of 19 serum pro-
teins have been performed in patients attending
a follow-uip clinic after radical resection of lulng
cancers. In 19 patients who developed clinical
evidence ofrecurrence during follow-up, changes
in one or all of 9 proteins occurred in 18, and
preceded clinical evidence of recurrence in 16.
The best markers of disease status were hapto-
globin and orosomucoid which were elevated in
15 patients, and increased serum levels of these
were foutnd uip to 10 inonths (mean 4-5 months)
before suggestive clinical, scan or X-ray evidence
of recuirrence.
Studies of these two proteins prior to opera-
tion have shown a significant correlation be-
tween the tumouir size and pre-operative sermiin
levels (]'<0-001) and betwTeen pre-operative
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levels and survival (P<0-01). Measurements of
serum haptoglobin and orosomucoid are of prog-
nostic value prior to operation, and serial deter-
minations after radical resection predict recur-
rence before other evidence in a high proportion
of patients. Haptoglobin has been shown to sUp-
press the in vitro responses of lymphocytes to
mitogens (Israel and Edelstein, Israel J. Med.
Sci., in press), and a primary or secondary role of
such proteins in modifying iinmunle status and
immunological responses to tumouir cells remains
to be elucidated.
GROWTH-HORMONE RESPONSE TO
A GLUCOSE-TOLERANCE TEST IN
CANCER PATIENTS WITH VARYING
DEGREES OF WEIGHT LOSS. P. F. M.
WRIGLEY, C. H. COLLIS, D. FIDDIAN and L. H.
REES, Department of Medical Oncology and
Chemical Pathology, St Bartholomew's Hospital,
London, EC1 and Dietetic Dept., Hackney
Hospital, London, E9.
Incomplete suppression or a paradoxical rise
in growth hormone (HGH) in response to an oral
glucose load (GTT) has been reported as a fea-
ture of endometrial carcinoma, and in associa-
tion with hypertrophic osteoarthropathy in car-
cinoma of the bronchus. Eighteen patients with
a variety of moderately extensive carcinomas
were assessed to find out whether there was an
association between such abnormal HGH re-
sponses and weight loss or anorexia. An assess-
ment of reduction in calorie intake and loss of
appetite was made from a full dietary history.
Half the patients had lost more than 100% in
weight compared with their pre-illness weight,
and half less than 10%. Two patients had per-
sistent high HGH levels following the GTT, one
of whom also had acromegalic features. Eight
patients had a mild paradoxical rise in HGH or
persistently moderately elevated HGH. These
patients' diagnoses included carcinoma of the
colon, rectum, pancreas, bronchus, breast, kid-
ney, adenocarcinomas of unknown origin and
Hodgkin's disease. In 8 patients there was nor-
mal suppression of HGH. Eleven patients had
diabetic glucose-tolerance curves. No relation-
ship between abnormal HGH response and
anorexia, weight loss or histological diagnosis
was seen.
IMPROVING CANCER THERAPY
TRIALS. R. PETO, Reader in Cancer Studies,
Radcliffe Infirmary, Oxford.
There are several hundred cancer trials cur-
rently in progress, and many will yield either no
information or misleading information, duie to
ei-rors of design. The cornmonest errors are:
1. Inadequate size. This is a fault ofmosttrials,
as in a trial involving only 100 cancer patients
medically important differences can easily be
swamped by random error. Collaboration with
other oncology clinics (perhaps through the
MRC collaborative trials) simplified documenta-
tion, non-restrictive eligibility criteria and an
active effort to make entry as rapid as possible,
may all help.
2. Nonrandomized designs which allow biases
to affect the comparison (e.g. using comparisons
with past patients instead of with present
patients).
3. Incomplete follow-up, either by intent
(ceasing to follow patients who deviate from
protocol) or by default (loss of patients who
move). It is not widely enough known that the
Government will, for a fee of £1 per patient,
provide mortality follow-up from central records
for the indefinite fuiture.
4. FExclusinn of "protocol deviants" from the
statistical analysis. The biases that can arise if
this is done are discussed in Section 13 of a 67-
page review paper on clinical trial methodology
recently published in the Br. J. Cancer (34, 585
and 35, 1) reprints of which will be made
available.
SEQUENTIAL ACQUISITION OF FIBRI-
NOLYTIC ACTIVITY AND GROWTH IN
AGAR IN CULTURES DERIVED FROM
RATBRAINSEXPOSEDTRANSPLACEN-
TALLY TO ETHYLNITROSOUREA. T. A.
HINCE and J. P. ROSCOE, School of Pathology,
Middlesex Hospital Medical School, London WI.
In a previous study (Hince and Roscoe, 1977,
Br. J. Cancer, 36, 401) we have demonstrated
that high plasminogen-dependent fibrinolytic
activity w-as associated with cell lines derived
from the brains of rats exposed transplacentally
to the carcinogen ethylnitrosourea (ENU). The
study has been extended with particular em-
phasis on the timing of the appearance of fibri-
nolytic activity and its relationship to the ability
of cells to form colonies in agar. Two cell lines
derived 90-91 days p.i. (45F) and 57-60 days
p.i. (45A) were fibrinolytic when tested (24th
and 26th transfers respectively) (Hince and Ros-
coe, 1978, Br. J. Cancer, in press) but, at this
stage, they did not grow in agar although they
became positive at subsequent transfers. More
detailed sttudies using a culture derived 2 days
p.i., BEIO, and two clones (BE1O-13 and BEIO-
7) derived at the 10th and 20th passages respect-
ively, confirmed the previous observations.
BE1O had low activity (measured as the % total
of positive colonies with 40-70 cells/colony) to
begin with (8% 14th passage) butgainedhigher
activity within a few passages (62-5% 17th
passage). However, growth in agar was not
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demonstrated until the 45th passage. The activi-
ties of the two clones, BE1O-13 and BE10-7,
were similar; both showed relatively high fibri-
nolytic activities (35-500o) at the 8th transfer,
but did not acquire the ability to grow in agar
for a further 20 passages (Roscoe and Claisse,
1976, Nature, 262, 314). Thus, in this system it
appears that, in culture, characteristics of trans-
formed cells are gained in sequence; fibrinolytic
activity being demoinstrable before growth in
agar.
CELL SURFACE PROTEOGLYCANS AND
GLYCOPROTEINS OF MOUSE BONE
MARROW CULTURE. J. T. GALLAGHER*
and T. M. DEXTERt, *CRC Department of
Medical Oncology and tPaterson Laboratories,
Christie Hospital, Wilmslow Road, Manchester.
A liquid culture system, in which haemopoie-
tic stem cells can be maintained for several
months (Dexter et al. (1977) J. Cell Physiol., 91,
335) provides a unique opportunity for studying
problems of stem-cell reguilation.
Foremost amongst these is the role of marrow
supportive stroma in the determination of stem-
cell commitment and proliferation. To this end,
glycoproteins and proteoglycans synthesized by
the marrow cultures were labelled by incubation
with 3H-glucosamine and Na2 35SO4; cell surface
and extracellular macromolecules were extracted
with trypsin/EDTA and the extract analysed by
NaCl-gradient elution from DEAE-cellulose. 3H-
labelled neutral and acidic glycoproteins were
detected in the early part ofthe gradient (0-0 3 M
NaCI), followed by two doubly-labelled (3H and
35S) peaks emerging between 0 5 M and 0-7 M
NaCl. Analyses by electrophoresis and chondro-
itiniase digestion showed that heparin sulphate
was the main suilphated proteoglycan, with
chondroitin stulphate, in all 3 isomeric forms, as
the minor component.
Hyaluronic acid was not a major 3H-labelled
mnacromnolecuile of the marrow matrix, although
small amounts might be present.
NUCLEAR-CYTOPLASMIC INTERAC-
TIONS IN MAMMALIAN CELLS AND
THE USE OF CYTOPLASMICALLY IN-
HERITED RESISTANCE DETERMI-
NANTS. I. CRAIG and E. MUNRO, Genetics
Laboratory, University of Oxford.
The availability of cytoplasmically inherited
drug-resistant determinants in some strains of
mamrnalian cell lines has enabled the construc-
tion of cell types combining nuclei and cyto-
plasm from different sources. This approach may
provide a way to evaluate the importance of
nuclear-cytoplasmic interactions to the expres-
sion of differentiated characters or to the deter-
mination of malignant phenotypes. We have
previously described the cytoplasmic transfer of
a determninant for chloramphenicol resistance
between different human cell lines and observed
that there are very distinctive strain and species
differences in the ability of cells to act as reci-
pients (AMtunro et al., 1978, Proc. R. Soc. Lond. B.,
in press).
Wre have recently obtained resultsfromfusions
betw%veen mouse cell lines froin strains carrying
two different cytoplasmically inherited deter-
minants, chloramphenicol resistance and oligo-
mycin resistance (Lichtor and Getz, 1978, Proc.
NVatl. Acad. Sci., in press). The results strongly
suggest that the hybrids preferentially retain
the cytoplasmic determinant (presumptive
mitochondrial DNA) from the chloramnphenicol-
resistant parent. Such observations provide new
insights into the interactions between the cell
nucleus and cytoplasmic genetic markers.
PLASMINOGEN ACTIVATION, AND
ACTIVATOR ALONE, INITIATE 3T3
CELL GROWTH TO ABNORMAL DEN-
SITIES. P. WHUR, J. J. SILCOX, J. BOSTON and
D. C. WILLIAMS, Marie Curie Memorial Founda-
tion, Oxted, Surrey.
Most malignant cells produce high levels of
plasminogen activator, but there appears to be
little good evidence of a correlation between
plasminogen activation and absence of density-
dependent inhibition in vitro. Confluent, quies-
cent 3T3 cells subjected to plasminogen activa-
tion by the addition of plasminogen and low
levels (10 Plough u/ml) of urokinase, grow to
super-confluent densities. Addition of urokinase
alone has no effect, but at high concentration
(200 ui/ml) the effects are the same as those pro-
duced by plasmninogen activation or plasmin;
disruption of the monolayer and growth to
higher densities. Since urokinase is a protease of
trypsin-like specificity, and there is evidence of
a close biochemical similarity to plasminogen
activator, we propose that the production of
high levels of activator alone may be sufficient
for transformed cells to grow beyond confluence
in the absence of plasminogen.
PLASMA ZINC AND COPPER: THEIR
RELEVANCE TO PROSTATIC DIS-
EASES. F. K. HABIB, T. C. DEMBINSKI,
M. R. G. ROBINSON* and S. R. STITCH, Division
of Steroid Endocrinology, Leeds and *Pontefract
General Infirmary, Pontefract, Yorks.
Total Zn and Cu plasma concentrations were
measured by atomic absorption spectroscopy in
62 untreated patients with benign prostatic
hypertrophy (BPH) and carcinoma of the pros-
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tate (CaP). Although the Zn levels in carcinoma
of the prostate were significantly lower than
those in the benign tissue (Habib et al., 1976,
J. Endocr., 71, 133) we were unable to correlate
the trace metal blood levels with the pathologi-
cal condition ofthe gland (P>1). Control studies
on a younger group of 14 subjects suggests,
however, a progressive increase in plasma Cu
levels with age; no similar trends were observed
with Zn.
Parallel investigations on 31 prostatic car-
cinoma patients receiving treatment with stil-
boestrol, estracyt or tamoxifen were also carried
out. A marked depression ofplasma Zn(P-<0-01)
and elevation of plasma copper (P<0-01) was
detected in the endocrine-treated patients.
These changes were most pronounced in subjects
receiving stilboestrol, suggesting that the levels
of the Cu and Zn are profoundly influenced by
oestrogens.
FAECAL BILE ACIDS AND CLOSTRIDIA
IN THE AETIOLOGY OF COLORECTAL
AND BREAST CANCER. A. BLACKWOOD,
W. R. MURRAY, C. MACKAY and K. C. CALMAN,
Departments of Clinical Oncology and Surgery,
Western Infirmary, Glasgow, Scotland.
Total bile-acid levels and the presence of
steroid nuclear dehydrogenating (ND) Clostridia
of cancer and non-cancer patients from the West
of Scotland were compared to investigate the
hypothesis that dietary fat has a role in the
aetiology ofcolon cancer (Hill et al., 1971, Lancet,
i, 95). Breast cancer has a similar epidemiology
to colorectal cancer, so patients with this form
of cancer were also included in the study. Mean
bile-acid levels (,mol/g freeze-dried faeces) for














The levels for patients with colorectal cancer
were significantly lower (P<0-05) than the con-
trols. This difference, however, is opposite to
that predicted by the hypothesis. This lack of
correlation has been found by another group
(Report from I.A.C.R. 1977, Lancet, ii, 207).
There was no difference between patients with
breast cancer and controls. A difference in the
occurrence of NDH Clostridia between controls
and cancer patients was observed. Of the con-
trols 53-8% had Clostridia, compared to 83-3%
of patients with colorectal cancer and 7899% of
patients with breast cancer. These figures indi-
12
cate that any relationship between faecal bile
acid, bacteria and the incidence of colorectal
cancer and breast cancer is not a simple one and
requires further study.
STUDIES ON A POSSIBLE VIRAL
AETIOLOGY OF CANINE LYMPHOSAR-
COMA AND MAMMARY TUMOURS.
S. J. ARMSTRONG, P. NUNES DE SOUZA*,
T. G. WREGHITTt, J. NAGINGTONt, B. W. J.
MAHY and L. N. OwEN,Depts.ofClinical Veterin-
ary Medicine, *Pathology (Virology) and tPublic
Health Laboratories, New Addenbrooks Hospital,
Cambridge.
Some evidence for oncornaviral involvement
in canine lymphosarcoma was found by Onions,
who demonstrated poly-rC oligo-dG templated
reverse transcriptase (RT) in 2 of 11 tumours
(1976, Ph.D. Thesis, Univ. of Cambridge).
In our experiments, culture supernatants from
3 leukaemic cases were positive by the RT assay.
10/11 lymphosarcomas were also positive, the
exception being an animal pretreated by irradia-
tion. 3H-uridine-labelled particles of a density
of 1-14-1-17 were produced in 3/7 of these cul-
tures. 2/3 leukaemic lymphosarcoma superna-
tants were positive by both criteriaandnegative-
stained preparations contained particles re-
sembling oncornavirus. The diameter of the
virus was 68 nm, whereas that of Rous Sarcoma
Virus was 94 nm.
Ten mammary tumours were cultured; 5 were
initially positive by RT assay, 4 grew into a
monolayer, 1 was continually positive, and this
activity was stimulated by progesterone and
dexamethasone. Virus particles similar to those
from the leukaemic material were seen.
TUMOUR-NECROSIS FACTOR FROM
THE RABBIT: IN VITRO STUDIES ON
ITS SPECIFICITY, MODE OF ACTION
AND SITE OF SYNTHESIS. N. MATTHEWS
and J. F. WATKINS, Department of Medical
Microbiology, Welsh National School of Medi-
cine, Cardiff.
Sera from rabbits injected with BCG and
then with endotoxin contain a factor (tumour-
necrosis factor-TNF) which, even at high dilu-
tions, is cytotoxic in vitro for mouse L cells and
some other cell lines but not primary embryo
fibroblasts. Sensitivity to TNF could not be
correlated with tumourogenicity for several
animal and human cell lines tested nor with the
production of C-type viruses. TNF was most
cytotoxic to metabolically active L cells and
acted on both dividing and non-dividing L cells.
It was effective at 37°C but not at 22°C or 4°C.
Rabbit TNF is remarkably stable with a mol.
wt. of 40-50,000. It was eluted with the more
acidic proteins on ion-exchange chromatography
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and precipitated in 50%o saturated aminonium
sulphate solution. A suibstance with similar
physico-chemical properties and cytotoxic speci-
ficity can be obtained from the supernatant of
rabbit peripheral-blood monocytes cultuired in
vitro.
THERAPY OF METASTASIZING RAT
TUMOURS OF SPONTANEOUS ORIGIN.
W. A. BASLEY, J. A. GREAGER, R. C. REES and
R. '. BALDWIN, Cancer Research Campaign
Laboratories, University of Nottingham.
Tilorone HCI is an antiviral drug which has
been show-n to induce high levels of circulating
interferon in the rat and is effective both orally
andparenterally. Adamson, (J. Natl. CancerInst.,
1971, 46, 131) has demonstrated its antitumour
activity against the Walker 256 carcinosarcoma
anid a reticulum-cell sarcoma grown s.c. whenthe
drug was injected i.p. We have uised the drug to
treat W'AB/Not rats bearing the spontarneously
arising carcinomas Spl or Sp22 which are not
known to be of viral aetiology. These tumours
will grow in a syngeneic host when implanted
s.c. or in the bi-east pad respectively, and after
10 days growth will metastasize to regional
lymph nodes and lungs. The injection of tilorone
HCI i.p. at various intervals during tumour
growth anid metastasis has been found to sig-
nificantly reduice the ntumber of tumour nodules
in the lung and increase the survival tine of the
anirnals.
These experimnents indicate that tilorone HCI
can influence the natuiral metastases which occur
wTith these spontaneouisly arising carcinomas.
INABILITY OF ANTICOAGULANTS TO
PREVENT PULMONARY METASTASES
IN MURINE BREAST CANCER. R. C. N.
WILLIAMSON, P. J. LYNDON and T. LAI, Depart-
rnent of Surgery, University of Bristol.
Warfarin inhibits both spontaneous pulinon-
ary inetastases (PM) in mice, and PM induced
by iv.. injectiorn of viable tumoumr cells (Hoover
et al., 1976, Surgery, 79, 625; Agostino and
Cliffton, 1962, Arch. Surg., 84, 449). Btit an in-
creased incidence ofextra-pulrnonarv inetastases
accomparnying similar inhibition of PM by he-
pariin suggests only an altered pattern oftuinouir
dissemination (Hagmar, 1970, Acta Plathol.
.ilicrobiol. Scand., 211, 1). Potential inhibition
of PM by anticoagulation with heparini or war-
farin was tested in A-strain mice (weight 20 g)
receiving a single i.v. injection of 0-5 or 1-0 x 106
viable tumour cells prepared fioin an A-strain
marnmary carcinoma. WNarfarin wvas added to
the di-inking water in doses (3 or 4 mg/1) sUffi-
cient to produce full anticoagulation, as tested
by Thrombotest (Nyegaard). Graded doses of
heparin (125, 250 or 500 u/kg) were given 8-
hourlly s.c. Anticoaguilatioii was starteld before
tumour injection and continued for 7-14 days














Despite causing full anticoaguilation, neither
heparin nor warfarin affected the development
of PM in this tumouir model.
COMBINATION HYPERTHERMIA (42°C)
AND HYPERGLYCAEMIA IN THE
TREATMENT OF THE YOSHIDA SAR-
COMA. S. K. CALDERWOOD and J. A. DICKSON,
CancerResearch (Jnit, University Dept. of Clinical
Biochemistry, Royal Victoria Infirmary, New-
castle.
The sensitization of neoplastic cells to hyper-
thermia at low intracellular pH (pHi) was re-
ported by von Ardenne (Adv. Pharmac., 1972,
10, 339). He described the use of prolonged (3-5
h) hyperglycaemia in vivo to stimulate tumouir
glycolysis and increase lactic-acid production.
The low tumour pHi, which he claimed ensued,
activated lysosomal enzymes to potentiate
hyperthermic damage.
Following hyperthermia (42°C/I h) the Yo-
shida sarcoma on the foot of rats regresses in
10-14 days with cure of the host. An increase in
blood glucose concentration (mean 400 mg %o)
for a 4 h period was induced in tumour-bearing
rats. Tumour lactate concentration doubled, and
extracellular pH, measured by micro capillary
glass electrode, fell from 7-2 to 6-6. The intra-
cellular pH of the sarcoma (measured by parti-
tioning of the weak organic acid dimethyloxazo-
lidinedione across the cell membrane) was un-
altered and glycolysis decreased. Tumour-
regression time following hyperthermia was
unaffected.
Hyperglycaemia, therefore, catused inhibition
rather than stimulation of glycolysis, and tui-
mour pHi was a stable property apparently buf-
fered against local increases in lactate coricentra-
tion. The destructive effects of hyperthermiia onI
the Yoshida tumouir wN-ere not potentiated by
hyperglycaemia.
CYCLOPHOSPHAMIDE AND REOXYGE-
NATION OF A RAT ADENOCARCINOMA.
B. DIXON and J. V. MOORE, Radiobiology De-
partmient and University Dept. of Radiotherapy,
Cookridge Hospital, Leeds.
Cytotoxic drugs in large doses, tolerable to the
host, are often capable of sterilizing a large frac-
tioi of cells within a solid tumourI' (UraIio et al.,
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1972, Gann, 63, 491; Moore and Dixon, 1978,
Eur. J. Cancer, 14, 91). This may lead to re-
oxygenation of surviving hypoxic cells and a
consequent improvement in the irradiation re-
sponse of the tumour. Hence 9±1 mm diameter
tumours transplanted s.c. in isogenic female
Wistar rats have been irradiated locally with
y-rays alone or, 1, 4, 7 and 10 days after an i.p.
injection of 150 mg/kg of cyclophosphamide.
The dose-response data, for delay in growth
of the tumour after irradiation alone under
normal or hyperbaric conditions of oxygenation,
is biphasic and, above 2000 rad, governed by a
hypoxic component of cells. Cell-survival assays
indicate that the tumour normally contains a
hypoxic cell fraction ofabout 20%, and that this
is reduced to 4% or less by hyperbaric oxygena-
tion.
One day after giving Cyclophosphamide the
response of the tumour in air-breathing animals
is the same as that obtained when the tumour is
clamped 15 mins prior to and during irradiation
suggesting that cells surviving drug treatment
are predominantly hypoxic. Three days later,
the hypoxic fraction is reduced but is still sig-
nificantly raised under normal aerobic condi-
tions. Only by 7 and 10 days had reoxygenation
reduced the hypoxic component to pre-drug
treatment levels. No indication of a residual
hypoxic component under hyperbaric oxygena-




SOMES IN NORMAL AND TUMOUR-
BEARING LYMPH NODES OF THE RAT.
V. J. RICHARDSON*, M. P. OSBORNEt, K.
JEYASINGHT, B. E. RYMAN* and J. I. BURNt,
Departments of *Biochemistry, tSurgery and
tNuclear Medicine, Charing Cross Hospital and
Charing Cross Hospital Medical School, London.
Using the rat Rd/3 foot-pad tumour model
(Carr and McGinty, 1974, J. Path., 113, 85), a
differential localization of interstitially-injected
99mTc-labelled liposomes (phospholipid vesicles)
in the primary regional lymph nodes (PRLN)
with and without tumour infiltration has been
observed. The results obtained with small nega-
tive (7:2: 1, PC:C:PA), positive (7:2: 1, PC:C:
SA) and neutral (8:2, PC:C) liposomes at 5 and





Our findings suggest that 99mTc-labelled
neutral liposomes may be a suitable lympho-
scintigraphic agent for the detection of lymph-
node metastases, since a marked suppression of
uptake of label was observed with neutral lipo-
somes when comparing normal and tumour-
infiltrated PRLN (P<0-01 at 5h and <0005
at 30 h). Cationic liposomes may potentially be
useful as carriers of therapeutic agents for the
treatment of lymiph-node metastases as these
liposomes localize well in both normal and tu-
mour-infiltrated PRLN.
IN VIVO ASSAY OF THE RADIATION
SENSITIVITY OF TUMOUR CELLS, IN-
FLUENCE OF MIXED MODALITIES. W.
PORSCHEN, J. GARTZEN, K. GEWEHR, H.-J.
WEBER, L. E. FEINENDEGEN, Institutfur Medi-
zin, Kernforschungsanlage, Julich, Germnany.
Tumour lysis can be evaluated in the living
mouse by externally measuring the rate of loss
of tumour-bound DNA tracer. By sequentially
labelling the tumour-bearing animals with
'25IUdR and 131IUdR 50 h apart, the average
tumour cells at the time of the second injection
are labelled by 125IUdR and the euoxic tumour
cells are specifically labelled with 131IUdR. Tu-
mour treatment at this stage oflabelling permits
the observation of the reaction of euoxic cells
and average tumour cells. This information adds
to results from tumour control andgrowth delay.
With this technique effects were analysed of
60Co y-rays, cyclotron neutrons (E= 6 MeV)
misonidazole (500 mg/kg) and hyperthermia
(42°C, water bath), or combinations of these.
Misonidazole (15 min before irradiation) altered
the oxygen-enhancement ratio by a factor of 1-5
for y-rays and 1 1 for neutrons; when evaluated
from tumour growth delay and TCD50 misoni-
dazole gave a dose-modifying factor of 1-47 for
y-rays and of 1-2-1-3 for neutrons.
Based on percent tumour regression 100 days
after treatment, the enhancement ratio from
hyperthermia (after irradiation) was 2 75 for
y-rays (at 10 Gray) and 2-2 for neutrons (at 3 2
Gray). For neutrons combined with misonidazole
and hyperthermia the ratio was 2-4.
These results demonstrate that effects of
neutron irradiation may be modified by electron-
affinic substances and/or hyperthermia.






















Mean±s.e. No. of animals in brackets. PC=Phosphatidylcholine. C=Cholesterol. 'SA=Stearylamine.
PA= Phosphatidic acid.
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OUTGROWTH OF TUMOUR EXPLANTS
AS A METHOD OF ASSESSING RE-
SPONSE TO THERAPY. N. J. McNALLY and
J. DE RONDE, Cancer Research Campaign Gray
Laboratory, Mount Vernon Hospital, Northwood,
Middlesex.
There is an urgent need to develop methods
for estimating rapidly and quantitatively the
response of human tumours to therapy. One
possibility is to use short-term explants. Needle
biopsies could provide sufficient material to be
cut into small pieces and attached to coverslips
by means of a coagulum. The assay would then
be to score the presence or absence of outgrowth
within a given time as a function of the treat-
ment received.
This method has been used to study the re-
sponse of mouse tumours to radiation. We have
compared the results with those based on mea-
surements of TCD50 and tumour-cell survival in
vitro following treatment in vivo. In particular,
we have measured the effects of clamping the
tumour before treatment, and of the hypoxic-
cell sensitizer misonidazole. The results suggest
that, in at least one of the tumours tested, the
explant technique can provide validinformation,
the effects ofthe clamp and sensitizer being what
would be expected from the other assays.
The method needs to be extended to other
types of experimental tumours before use with
human tumours. However, besides its practical
potential, the method is applicable to problems
of tumour radiobiology for which established
techniques may not be suitable.
GROWTH DELAY ANALYSIS FOR THE
CELLULAR RADIOSENSITIVITY OF A
MURINE TUMOUR. T. E. WHELDON, A. S.
ABDELAAL and A. H. W. NIAS, Glasgow Institute
of Radiotherapeutics and Oncology, Belvidere
Hospital, Glasgow.
Analysis of radiation growth-delay experi-
ments is complicated by the occurrence of nor-
mal tissue damage as well as tumour-cell kill,
both effects contributing to the observed delay.
We have approached the problem by combining
growth-delay data with data obtained from
single-dose radiocurability experiments.
For the C3H mouse mammary carcinoma we
find the radiation TCD37 to be 65 Gy and the
mean delay induced by this dose to be 73 days.
Since, from Poisson statistics, the TCD37 is that
dose which leaves one surviving cell on average,
and the delay is recorded as time to grow to 108
cells, the mean doubling time can be calcuilated
as 2-75 days.
We may then calculate Do for the most re-
sistant clonogens from growth delay, for a dose
range in which constancy of doubling time is
indicated by linearity of the dose-delay relation.
In the range 60-70 Gy, with extrapolation num-
ber assumed 1-10 and proportion of resistant
clonogens assumed 0.01-1O00, the extreme esti-
mates of Do are 3-5 Gy, with 3-9 Gy the most
reasonable number. These findings, which are
relatively insensitive to the numerical assump-
tions, to tumour-size variations and to variations
in dose, are consistent with the resistant clono-
gens being hypoxic cells.
Growth-delay analysis, with knowledge of the
single-dose TCD37, holds promise as an in vivo
method for the estimation of cellular radio-
sensitivity of experimental tumours.
REPOPULATION OF y-IRRADIATED
LEWIS LUNG CARCINOMA BY TU-
MOUR CELLS AND HOST CELLS. T. C.
STEPHENS, G. CURRIE and J. H. PEACOCK,
Institute of Cancer Research, Sutton, Surrey.
We have studied cellular repopulation in the
Lewis lung carcinoma after irradiation with
60Co y-rays. Colony formation in soft agar was
used to evaluate cell survival. After local irra-
diation (15-35 Gy) two types of colonies were
seen, some with tightly packed cells (compact)
and some with diffusely scattered cells (diffuse).
After whole-body irradiation only compact
colonies were seen. It was found that only cell
survival calculated from compact-colony counts
correlated well with survival obtained by the
lung-colony assay and that the compact-colony
forming cells repopulated with a doubling time
of about 1 day, which agreed well with tumour-
volume regrowth. Following local irradiation
(15-35 Gy) the number ofdiffuse-colony forming
cells per tumour was reduced to less than 1/100
of the pretreatment level. Diffuse-colony form-
ing cells repopulated the tumours much more
quickly than compact-colony forming cells.
We conclude that at least two populations of
clonogenic cells are present in the Lewis lung
carcinoma, tumour cells which form compact
colonies in agar and repopulate the tumour by
in situ proliferation, and host cells which pro-
duce diffuse colonies in agar and can repopulate
locally irradiated tumours by infiltration.
KINETICS OF IMMUNE DESTRUCTION
OF MALIGNANT CELLS IN THE RAT:
STUDIES WITH 1251UDR-LABELLED
SYNGENEIC CELLS. M. V. PIMM, Cancer
Research Campaign Laboratories, University of
Nottingham.
The rate ofdeath ofsyngeneically transplanted
rat tumour cells in normal, tumouir-immune,
and BCG-treated rats has been determined by
monitoring urinary excretion of 1251 from
125IUdR-labelled cells (Porteiis and Munro,
1972, Int. J. Cancer, 10, 112).
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With an ascitic hepatoinia, rats receiving cells
pie-labelled in vitro or in vieo showed 10-20%
urirnary excretion of residual 1251 activity per
24 h period, developing ascitic growths after
15-20 days, comparable to growth from un-
labelled cells. Rats receiving heat-killed oIr
irradiated cells lost 35-60% of residual isotope/
24 h, starting 24 h after cell injection. Animals
immune to the tumour showed a simnilar, 60%/
day loss, but beginning immediately after cell
inoculation. I.p. injection of BCG together with
labelled cells prevented their growth, but did
not accelerate loss oflabel within a 6-day period.
However, rats pre-treated 4-10 days previously
with BCG showed increased 125I exeretion iun-
mediately after cell injection. Coinparable tests
wTith solid s.c. growths from hepatoma or sar-
coma cells showed slight increases in excretion
oflabel, starting 24 h after injection, from inocu-
la prevented from growth by admixtuire with
BCG. Here, however, excretion was not detect-
ably accelerated from heat- or radiation-killed
cells, or in tumour-immuine animnals, over a 6-
day period, although with solid i.p. grow\ths
urinary loss of label was increased from ir-
radiated or heat-killed cells.
These studies indicate that urinary loss of
isotope from labelled cells may be used as an
index of the rate of immunotherapeutic destruc-
tion of turmour cells in syngeneic models, but
suggest that ascitic or i.p. growths may be more
easily studied than solid s.c. tuinouirs.
KINETICS OF IN VIVO CELL DESTRUC-
TION AFTER VARIOUS CHEMOTHERA-
PIES. S. ORBACH-ARBOUYS, J. LHERITIER, M. B.
CASTES an1d P. POUILLART, Institut de Cancero-
logie etd'Imnmunogenetique, 16 AvP. V. Coututrier,
Villejuif.
A variety of drugs are administered to BDF1
mice after the injection of 107 125IUdR-labelled
L1210 leukaeinic cells. The fall of radioactivity
allows Us to define 2 types of cell destruction:
one, immediate, intense, short-lasting (adriainy-
cin, Ara-C, VM26, MTX, VCR) the other, inuch
less intense, but long-lasting (5FU, Natulanl,
DTIC). Some drugs belong to an intermediaiy
group (cyclophosphamide, methyl CCNU,
CCNU). Drugs of the 1st group, by rapidly
eliminating ttumour cells, could be considered as
good recruiiting agents (adriamnycin, VCR, in
particular). They are the first to be given in
cornbined chemotherapy.
Among the drugs of the 2nd grouip, soine may
have an important effect on sturvival. 5FU in-
jected after 107 L1210 cells doubles the surxvival.
Since we have previously reported the important
role of inacrophages in tumour-cell destruction,
and since the 5FU effect is entirely abolished
by sio2 or BCG given at the same time, we
propose as an explanation of our observation
that the drug has induced long-lasting altera-
tions in the leukaemic cells which are then
progressively destroyed by the macrophages.
THE EFFECT OF 5-FLUOROURACIL
ON THE GROWTH OF ASCITIC, DIS-
SEMINATED AND SOLID FORMS OF A
MODEL COLONIC ADENOCARCINOMA.
S. O'HARE and J. A. DOUBLE, Unit for Cancer
Research, University of Leeds.
5-Fluorouracil (FU) is at present the drug
most widely used against colonic adenocarcino-
mias; administration is usually via the i.v. route.
This report describes the effects of i.v. FU on 3
biological forms of a mouse model adenocar-
cinoma.
MAC 15A is a transplantable mouse colon
tumnour. Iv. injections of tumour-cell suspen-
sions into normal mice produce disseminated
tumour foci. S.c. injections produce solid tu-
mnours at the site of injection. Mice received a
single i.v. dose of 200 mg/kg FU.
This dose produced an 87-7% cell kill against
the ascitic form, 41-3% cell kill against the dis-
semninated form, and 56.5% inhibition of the
solid form.
Although the percentage cell kill in the ascitic
system is more than twice that produced against
the disseminated tumour, the relative percent-
age increase in median survival time was only
3-4°, indicating that an apparent two-fold dif-
ference in cell kill has very little biological
significance.
Direct comparison of these 2 tumour forms
with the solid tumour system is difficult, since
we are unable to calculate a percentage cell kill
in the latter case. However, the quantitative
results obtained in the ascitic and disseminated
systems show a good correlation with the quali-
tative results found in the solid system.
PHARMACOKINETICS OF 5-FLUORO-
URACIL. H. W. VAN DEN BERG, R. F. MURPHY
and B. J. MCDERMOTT, Department of Bio-
chemistry, Queen's Unieersity, Belfast.
The pharinacokinetics of 5-fluorouracil (FU)
in patients undergoing combination chemo-
therapy for breast cancer, has been investigated
using a novel GLC electron-capture assay tech-
nique which is capable of detecting 20 ng FU
per rnl plasma. The concentration of FU in
plasma fell rapidly during the first hour after
i.v. injection. A rapid distribution phase (t1/2
5-0 mimi, range 3-0-8-0 min) was followed by a
seconid phase (t1/2 11-8 min, range 6-9-22-8
min). During this period a second peak appeared
in GLC profiles of plasma extracts, and there is
evidence to suggest that it represents 5-6 dihy-
drofluorouracil, a major catabolite of FU. This
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is eliminated from the plasma with a half-life of
-1-5 h. A terminal phase in the elimination of
FU from plasma has been observed (t1/2 -1L3
h). It is suggested that the second rapid phase
of drug elimination reflects metabolism and
urinary excretion, and that the terminal phase
represents loss of FU in equilibrium with the
intracellular anabolic pool, which would include
the postulated active metabolite of the drug.
THIAMINE VITAMIN B1 STATUS IN
CANCER PATIENTS AND THE EFFECT
OF 5-FLUOROURACIL THERAPY. M.
SOUKOP and K. C. CALMAN, Department of
Clinical Oncology, 1 Horselethill Road, Glasgow.
Major nutritional abnormalities in cancer
patients are often recognized, but despite the
specificity and sensitivity of the red-cell trans-
ketolase method for thiamine status, little is
known of any vitamin B1 levels in cancer
patients. 5-Fluorouracil (FU) functions as a
cocarboxylase antagonist in vitro in the trans-
ketolase reaction. The aim, therefore, of the
present study was to investigate the thiamine
status by the transketolase method and the
effect of FU therapy in cancer patients. Of 95
cancer patients 36-8% were found to have bio-
chemical evidence of thiamine deficiency, com-
pared to 10-9% of 46 healthy controls (P<0-01).
Twenty-four cancer patients had further thia-
mine estimations performed 24 h after initial i.v.
therapy with FU 15 mg/kg body weight. Only
2/14 patients with initially normal thiamine
status developed biochemical evidence of defi-
ciency on FU therapy. Both of these had initial
borderline deficiency levels. Nine of 10 patients
with initial biochemical deficiency developed an
exaggerated deficiency state after FU therapy.
One patient on long-term weekly i.v. FU therapy
developed clinical evidence of thiamine defi-
ciency. Replacement therapy improved the
symptoms and signs of the deficiency state, but
coincided with rapid tumour progression. In
conclusion, cancer patients are at risk of sub-
clinical or clinical thiamine deficiency, which, if
present, can be aggravated by FU therapy.
Routine prophylaxis with additional thiamine
may, however, be detrimental.
SUBSTITUTED QUINAZOLINES AS
ALTERNATIVE ANTIFOLATES. R. M.
PAINE, A. H. CALVERT, T. R. JONES, B. GRZE-
LAKOWSKA-SZTABERT and K. R. HARRAP, Dept.
Biochemical Pharmacology, Institute of Cancer
Research, Sutton, Surrey.
The value of methotrexate (MTX) in cancer
chemotherapy may be compromised by the de-
velopment of drug resistance. This may be due
to diminished cellular uptake via the reduced
folate pathway, or to increased intracellular
dihydrofolate reductase (DHFR) levels. In the
former case, an antifolate utilizing the folate
pathway for uptake would overcome resistance,
while in the latter, enzyme kinetic considerations
indicate that inhibition of both DHFR and
thymidylate synthetase may be of value.
We report experiments on two substituted
quinazolines, N-[p-[[(2,4-diamino-5-methyl-6-
quinazolinyl)methyl]amino]benzoyl]-L-glutamic
acid (CB 3703) andN-[p-[[(2-amino-4-hydroxy-6-
quinazolinyl)methyl]amino]benzoyl]-L-glutamic
acid (CB 3705). CB 3703 inhibits DHFR as
effectively as MTX, and also inhibits thymidy-
late synthetase. Its toxicity to cultured L1210
cells is comparable with that ofMTX, and is re-
versed by thymidine/hypoxanthine or thymi-
dine/folinic acid combinations. It is transported
via the reduced-folate pathway, but reaches
higher intracellular levels than MTX. CB 3705
also inhibits DHFR and thymidylatesynthetase.
Its toxicity in vitro may be reversed either by
folinic acid or by thymidine alone. It is trans-
ported via the folate pathway.
These studies indicate that substituted quina-
zolines may represent useful alternatives to
MTX.
A RAPID METHOD FOR THE DETER-
MINATION OF PURINE AND PYRIMI-
DINE NUCLEOSIDES AND BASES IN
PLASMA. G. A. TAYLOR, P. J. DADY, S. E.
BARRIE and K. R. HARRAP, Dept. Biochem.
Pharmacol., Institute of Cancer Research, Sutton,
Surrey.
We have established that high-dose metho-
trexate followed by purine/pyrimidine rescue is
superior to methotrexate with folinic acid res-
cue, in terms of antitumour activity. High-dose
methotrexate with purine/pyrimidine rescue has
now been approved for clinical evaluation. In
preparation for this, we have evolved a rapid
sensitive method for the determination of cir-
culating plasma levels of relevant nucleosides
and bases. We present data showing basal levels
ofthe major purines and pyrimidines circulating
in mouse and man, and the half-lives of the
rescuing agents in mice.
CYTOSINE ARABINOSIDE PHARMA-
COKINETICS IN ACUTE MYELOID
LEU-KAEMIA. A. L. HARRIS, J. BOUTAGY and
D. HARVEY*, M.R.C. Clinical Pharmacology
Unit, Radcliffe Infirmary, Oxford and *Univ.
Dept. Pharmacology, Oxford. (Introduced by Dr
T. R. Munro.)
There is wide inter-individual variation in
cytosine arabinoside (Ara-C) metabolism, with
plasma half-lives varying from 5 min to 2 h (Ho
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and Frei, 1971, Clin. Pharmacol. Ther., 12, 941).
It has been suggested that pharmacokinetic dif-
ferences may be related to remission induction
(Prooijen et al., 1977, Clin. Pharmacol. Ther., 21,
744).
We have studied Ara-C pharmacokinetics in
new patients with acute myeloid leukaemia.
Ara-C was given i.v. as a bolus of 2 mg/kg, and
serial blood samples taken from 3 min to 6 h
afterwards. Plasma Ara-C levels were also
monitored in patients receiving i.v. infusions.
Plasma samples were assayed by gas-liquid
chromatography (GLC) or GLC-mass spectro-
scopy. The sensitivity of the former was 50 ng
Ara-C/ml, ofthe latter, 1 ng Ara-C/ml.
Twelve patients received boluses. In 8, the
drug was eliminated from the plasma in a bi-
phasic or triphasic manner with a terminal t1/2
of 7-66 min. In the remaining 4, levels declined
below the limit of detection by GLC with ap-
parent t1/2 of 2-2-4-7 min. Clearances ranged
from 3-9 to 11-6 1/min. Infusions were monitored
in 16 patients, including 7 ofthe 12 who received
a bolus. Dosages were 5 mg to 2 g ofAra-C/24 h.
The plasma concentrations ranged from 5-4 to
650 ng/ml and clearance from 0-39 to 4-4 1/min.
There was no correlation of age, weight, sex,
renal function or remission with clearance.
We conclude that rather than adjust doses by
body weight, constant i.v. infusion of 65 mg
Ara-C/24 h for 5-7 days would give plasma
concentrations in the range of 10 ng to 100 ng/
ml in all patients here studied.
CONTINUOUS LOW-DOSE INFUSIONS
OF ARA-C IN THE MANAGEMENT OF
PATIENTS WITH AML. C. G. POTTER, C.
BUNCH, M. J. PIPPARD and A. C. ROWELL,
Nuffleld Department of Clinical Medicine, Univ.
of Oxford.
The action ofAra-C is mainly S-phase specific,
producing inhibition ofDNA synthesis by block-
ing DNA polymerase. Incorporation of the drug
into DNA and effects on RNA synthesis may
also be cytotoxic, especially at high concentra-
tions. Work presented shows that the sensitivity
of AML cells to Ara-C varies widely (as deter-
mined by the dose-response of 3HTdR inhibition
during 30 min incubations) and a differential
sensitivity was found at low Ara-C concentra-
tions for many leukaemic marrows compared
with normal controls.
The present study on 18 patients attempted to
exploit the low-concentration effect. Ara-C was
given by continuous infusion at a low dosage
(10-80 mg/d) calculated from the individual
sensitivity of the leukaemic cells and pharma-
cological clearance data. Initial progress and
subsequent dose-adjustment was determined by
the rate of peripheral blast loss, which was con-
sidered adequate if in the range (1-3) x (marrow
3HTdR-labelling index). Conventional combina-
tion chemotherapy replaced the infusions after
10 weeks, though earlier if response was in-
adequate or toxicity unacceptable. Seventeen
patients showed a measurable anti-leukaemic
effect of the infusion. Overall remission rates
were comparable with other series, and infusions
were well tolerated.
THE EFFECT OF IMMUNOTHERAPY
ON PHENYTOIN METABOLISM IN
MAN. H. H. WAN, P.W. MULLEN, N. THATCHER
and P.M.WILKINSON, Depts. ofClinicalPharma-
cology and Medical Oncology, Christie Hospital
and Holt Radium Institute.
Animal studies have demonstrated that im-
munotherapy will depress hepatic metabolism
which is most evident 7-13 days after treatment.
Since immunotherapy and chemotherapy are
often used together in the treatment of dissemi-
nated tumours, we have studied the influence of
BCG and C. parvum on phenytoin metabolism in
man. Serial serum phenytoin concentrations
were determined in 8 patients after a single oral
dose of phenytoin sodium (Epanutin, Parke-
Davis) before and after immunotherapy. Four
healthy volunteers served as controls. No sig-
nificant difference was observed within patients
in the area (mg/R/l) beneath the serum con-
centration/time curves and the values of Km
and Vmax derived from the individual concen-
tration time curves, after the 2 phenytoin tests.
Similarly, no significant difference was observed
in the proportion of 5-(p-hydroxyphenyl) to 5-
phenylhydantoin excreted in the urine during
the first 72 h after administration. We conclude
that BCG and C. parvum had no effect on pheny-
toin metabolism.
IMMUNOGENICITY OF SPONTANE-
OUSLY ARISING TUMOURS IN INBRED
RATS. J. G. MIDDLE and M. J. EMBLETON,
Cancer Research Campaign Laboratories, Univ.
of Nottingham.
Tumours arising spontaneously in highly in-
bred W/Not rats have been established as lines
by passaging in syngeneic hosts. The immuno-
genicity of these tumours has been assessed
using in vivo challenge-protection methods. Rats
were immunized by surgical excision of s.c.
growing transplanted tumours, or by implanta-
tion of attenuated tumour tissue or cells. After
immunization they were challenged with viable
suspended tumour cells, initially at low doses;
progressively higher doses were administered at
regular intervals thereafter until progressive
tumour growth occurred. Tumour growth in
immunized and control rats was compared to
give an assessment of tumour immunity.
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A total of 23 spontaneous tumours of various
types have so far been studied and 7 of these
have proved to be immunogenic. In some cases
the levels of immunity induced were very low,
but with some tumours it was possible to induce
levels of specific immunity equivalent to those
commonly observed with chemically induced
tumours.
MAREK'S DISEASE TUMOUR-SPECIFIC
ANTIGEN (MATSA) INDUCED BY THE
HERPESVIRUS OF TURKEYS (HVT) IN
VACCINATED CHICKENS. P. C. POWELL
and M. RENNIE, Houghton Poultry Research
Station, Houghton, Huntingdon, Cambs.
Since 1970, vaccination against Marek's
disease (MD) has effectively controlled this in-
fectious lymphomatous disease of chickens, but
the basic mechanism of protection is still ob-
scure. Antibody and cell-mediated immune re-
actions to MD virus-specific antigens have been
observed, but the demonstration that birds im-
munized with tumour-specific antigens were pro-
tected against MD, the pathological observation
oflesion regression and the conflicting reports of
the presence in vaccinated chickens of lympho-
cytes cytotoxic to tumour cells, all suggested
that an anti-tumour immune response may also
be important. Hitherto, however, it has not
been possible to demonstrate that vaccine
viruses induce the tumour-specific antigen,
MATSA. Living cell suspensions prepared from
the tissues and blood of chickens vaccinated
with HVT were examined for the presence of
MATSA-bearing cells, by membrane immuno-
fluorescence. Positive cells formed a small pro-
portion (up to 2%) of total lymphocytes, par-
ticularly in the spleen, from 10 days after vac-
cination until the end of the experiment at 66
days post-vaccination. These low levels of posi-
tive cells contrasted with the much higher levels
(up to 30%) observed in tissues from chickens
infected with a virulent strain of MD virus. The
presence of MATSA-positive cells in chickens
vaccinated with HVT supports the proposal
made by Payne et al. (1976, Int. Rev. Exp. Path.,
16, 136) that an immune response against this
antigen has an essential role in the mechanism
of vaccinal immunity.
DEVELOPMENT OF A CELL MEDIATED
IMMUNE RESPONSE TO ENCEPHALI-
TOGENIC FACTOR IN RATS DURING
HEPATOCARCINOGENESIS. D. J. FLA-
VELL, J. GOEPEL, C. W. POTTER and I. CARR,
Dept. of Pathology, Weston Park Hospital,
Sheffield and the Academic Divn. of Pathology,
Sheffield University.
A delayed hypersensitivity response to en-
cephalitogenic factor (EF) detected with the
macrophage migration inhibition (MMI) test has
been demonstrated in human cancer patients
(Flavell and Potter, 1978, Br. J. Cancer, 37, 1)
and in women with dysplastic cervical lesions
(Singer et al., 1975, Br. J. Obst. Gynaecol., 82,
820). The demonstration of such a response in
women with dysplasia suggests that lymphocyte
sensitivity to EF appears before clinically de-
tectable carcinoma. Using an animal model in
the present study we have attempted to define
the point during tumour progression at which a
delayed hypersensitivity response to EF first
becomes apparent.
The development of a spleen-cell response to
EF was investigated in Wistar rats during the
course of hepatocarcinogenesis with 4-dimethyl-
amino-3-methylazobenzene. A spleen-cell re-
sponse to EF as determined with the direct
MMI test was detected in 2/10 (20%) animals
with minimal changes in the liver, in 2/16 (12%)
animals with proliferative hepatic changes, in
7/13 (46%) animals with dysplastic lesions of
portal tract epithelial cells and in all 5 animals
with cholangiocarcinoma. None of a group of 10
control animals showed any response to EF.
Abrogation of the spleen cell response to EF by
autologous serum was seen in one sensitized
animal with proliferative hepatic changes, in all
7 sensitized animals with dysplastic hepatic
lesions, and in 4/5 sensitized animals with
cholangiocarcinoma.
These results suggest that a spleen-cell
response to EF and associated serum blocking
activity occurs in association with carcinogen-
induced dysplastic hepatic lesions in rats before





CELLS. M. J. EMBLETON and R. W. BALDWIN,
Cancer Research Campaign Laboratories, Univ.
of Nottingham.
Freshly prepared cells of whole 18-19-day rat
embryos were inoculated for 18 h in vitro with
10 jug/ml 3-methylcholanthrene (MCA) or with
medium containing its solvent (DMSO). The cells
were then washed x 6 and injected i.p. into syn-
geneic male rats at a dose of 108 cells per rat.
This immunization was performed x 4 at 10-day
intervals, using a different preparation ofembryo
cells on each occasion. The rats were bled 10 days
after the 4th injection and their serum tested for
antibody reacting with cells of established
chemically induced rat tumours, using a mem-
brane immunofluorescence test.
Sera from rats immunized with DMSO-treated
cells were completely inactive; but sera from
rats immunized with MCA-treated cells reacted
with established tumours in about 1/6 of the
combinations tested. This antibody activity was
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reproducible, and specific for certain tuinours.
It is concluded that the individual antigens of
chemically induced tumours are not unique, and
similar specificities may be reproduced evenafter
short-term carcinogen treatment.
FACTORS INFLUENCING THE ANTI-
GENICITY AND IMMUNOGENICITY OF
RADIATION-ATTENUATED AMINO-
AZO DYE-INDUCED RAT HEPATOMA
CELLS. R. G. DENNICK and M. R. PRICE,
Cancer Research Campaign Labs., Univ. of
Nottingham.
Brief treatment of y-irradiated (15,000 R) rat
hepatoma cells with various concentrations of
glutaraldehyde at room temperature, markedly
influences their capacity to immunize syngeneic
rats against subsequent challenge with viable
hepatoma cells. Exposure to glutaraldehyde (at
concentrations from 0-5% to as low as 0-001%)
abolished their immunogenicity and prevented
tumour-specific-antibody formation. However,
treatment with glutaraldehyde did not modify
tumour-specific antigens demonstrable by the
binding of antibodies in syngeneic immune sera
visualized by indirect membrane-immunofluo-
rescence-staining oftreated cells, and alloantigen
expression remained unaffected as assayed
using a quantitative radioisotopic antiglobulin
assay. Also, treated cells specifically absorbed
antibody from syngeneic sera, as judged by in-
direct membrane immunofluorescence or using a
51Cr-release test. Lactoperoxidase-catalysed
radioiodination of glutaraldehyde-treated hepa-
toma cells, followed by polyacrylamide-gel
electrophoresis in the presence ofsodium dodecyl
sulphate and f-mercaptoethanol, provided evi-
dence for considerable cross-linking of surface-
membrane components. It can be concluded
that, although the expression of a tumour-speci-
fic antigen may be necessary for effective
immunoprotection, this alone is not a sufficient
criterion for the induction of immunity. More
detailed analysis of this model for defining fac-
tors influencing tumour-specific antigenicity and
immunogenicity will allow identification of the
parameters required for the full expression of
tumour immunity.
RESPONSES IN THE DRAINING LYMPH
NODE OF TUMOUR BEARING RATS
DURING BCG CONTACT THERAPY. G.
ROBINSON, J. A. JONES and R. C. REES, Depart-
ment of Pathology, Cancer Research Campaign
Laboratories, Univ. of Nottingham and Dept. of
Virology, Univ. ofSheffteld.
Using a transplantable rat hepatoma (D192A)
model, the histological and immunological
changes in the draining lumbar node were in-
vestigated after i.m. implantation in the hind
limb of syngeneic rats of either hepatoma
(D192A) cells alone or an admixture of D192A
cells and BCG. Implantation with D192A cells
alone produced a large palpable tumour, with
little evidence of infiltrating lymphocytes or
macrophages, by the 4th week. The draining
lumbar node showed an early cell-mediated re-
sponse in the T-dependent paracortex which was
maintained for 3 weeks and then declined rap-
idly. A humoral response, with activation of the
B-dependent cortex and subsequent appearance
of circulating specific antibody began in the 2nd
week and continued throughout tumour growth.
No palpable tumour developed from the ad-
mixture of D192A cells and BCG but, a massive
granulomatous reaction, in which the predoini-
nant cell type was the macrophage, was detected
by histology at the implantation site. In the
draining node the early paracortical response
was greater than that caused by tumour cells
alone and the paracortex also contained nu-
merous macrophage granulomas. This cell-
mediated response was maintained throughout
the period. However, only a slight humoral
response was observed. The admixture of
D192A cells and BCG protected the animals
from both simultaneous and subsequent D192A
tumour challenge at the contralateral intra-
muscular site.
ERYTHROCYTE ELECTROPHORETIC
MOBILITY: EFFECT OF LYMPHOCYTE
SUPERNATANTS. J. E. D. DYSON (intro-
duced by J. P. DICKINSON), Y.C.R.C. Labora-
tory, Univ. Dept. of Radiotherapy, Regional
Radiotherapy Centre, Cookridge Hospital, Leeds.
Porzsolt, Tautz and Ax (1975, Behring Inst.
Mitt., 57, 128) have described a study in which
tanned and fixed sheep erythrocytes were used
as indicator cells in the Macrophage Electro-
phoretic Mobility (MEM) test. I have made a
systematic study of the use of tanned erythro-
cytes as indicator cells under similar conditions
to those employed by Porzsolt et al., employing
myelin basic protein (MBP) as "antigen".
My results show that MBP, at a concentration
of 330,ug/ml, reduces the electrophoretic mo-
bility of erythrocytes by -75%, but that if
MBP is pre-incubated for 24 h with lymphocytes
from normal subjects, the same concentration
of MBP is only able to reduce the mobility by
5 to 10%. If, however, the lymphocytes are from
patients with malignant disease, the residual
slowing capacity of the MBP, at the same con-
centration, is about 30 to 40%. These values are
dependent on lymphocyte number, MBP, con-
centration and time of pre-incubation and the
influence of these parameters has been deter-
mined in order to optimize the difference
between the two groups.
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As pre-incubation with lyimiphocytes fromii
patients with malignan-t disease results in a level
of residual slowing some 25 to 30%o higher than
that observed with lymphocytes fromr normal
controls, this provides a possible method for
identifying subjects with malignant disease. My
resuilts thus to sorne extent support those of
Porzsolt et al. However, I do not consider, as
they do, that this is a modification of the MEM\NI
test. The results obtained are more consistent
with the method depending on a non--imninuno-
logical property of the lymphocyte.
IMMUNOLOGY OF NAEVI AND MELA-
NOMA-IN-SITU. A. J. COCHRAN, N. I. L.
WILSON, C. E. BIoss, B. M. MACKIE, L. J. OGG
and G. TODD, Departmnents of Pathology and Der-
miatology, WVestern Infirmary, Glasgow.
Extracts w-ere prepared fIroin 15 malignant
melanomas, 10 simple naevi, 4 pieces of peri-
melanomatous skin, 4 pieces of skin from areas
of lentigo mnaligna and 4 pieces of normal skin.
These were tested, using a capillary leucocyte-
migration assay, against leucocytes from 52
patients w-ith benign nae-vi, 57 with malignant
melanomas and 98 normal individuals. Melano-
ma extracts preferentially inhibited the mnigra-
tion of leucocytes from patients with malignant
melanomas and naevi. Naevus extracts selec-
tively inhibited the leuicocytes of patients with
malignant melanoma. Extracts of skin contain-
ing cytologically atypical melanocytes (peri-
melanomatouis skin and lentigo inaligna)
selectively inhibited the migration of melanoma
patients' leucocytes, buit showed no prefererntial
activity for naevus leucocytes.
HISTOPATHOLOGICAL SPECIFICITY
OF THE LAI MICROTEST IN BRON-
CHIAL CARCINOMA. H. M. ANTHONY and
C. MILLBAND, Dept. of Imnniunology, School of
Medicine, Leeds.
Highly puirified plasma-ineinbrane. fractions
have been prepared from squamous cell, oat cell
(small), undifferentiated and adenocarcinomas
of bronchus, using the method of Bell and See-
tharum (1976, Int. J. Cancer, 18, 605). The
antigens have been tested against leucocytes
from 4-6 ml blood (preservative-free heparin) in
a modification of the LAI microtest (Holt et al.,
1975, J. Immunol. M1ethods., 8, 277) using RPMI
1640 wvith 0-10% crystalline BSA.
This paper reports the results of68 consecutive
tests, most using the squamous and oat antigens
(67, 68) and a tumour basic-protein preparatioin
(CTA)-cell (61) kiindly provided by Dr J. P.
Dickinson, and later tests also the adenoca. (30)
and tindiff. (29) antigens. The squamous, adeno-
ca. and undiff. antigens gave significant inhibi-
tion respectively in 29/37 (780o), 2/2, and 3/3
tests in patients with the same histopathology;
4/12, 3/16, 3/14 with other bronichial carcinomas;
2/12, 0/8, 0/83 with other chest diseases (Ca.
Bronchus cannot yet be excluded) and none in 4
other cancers or 2 normnals. The oat antigen did
not show histopathologic specificity. CTA Nas
positive in 30/43 tests in bronchial carcinoma
(70%) and in 0/4 other cancers.
Of the 47 tests using a battery of antigens
including the histopathologically corresponding
antigen in primnary bronchial carcinoina, 91%
wAere positive with one or more lung cancer
antigen.
SURFACE ANTIGENS IN ACUTE MYE-
LOBLASTIC LEUKAEMIA: LACK OF
TUMOUR SPECIFICITY. L. TUPCHONG and
I. C. M. MACLENNAN, Nuffield Departnment of
Clinical Medicine, Radcliffe Infir-mary, Oxford.
Immunotherapy trials in A'IL are partially
based on the presuined existence of immuno-
genic leukaemia-specific antigens. We have
attempted to demonstrate the presence of these
antigens by producing an AMIL-specific hetero-
logous antiserum. Ninety-foumr antisera, pro-
duced in rabbits, were analysed by an LDA
cytotoxicity test and by a 1251 labelled anti-
immunoglobtilin binding assay. The immunizing
mnyeloblasts included the following: untreated
whole cells, neumraminidase-treated cells, gluter-
aldehyde-fixed cells, normal antigen-blocking
serum (NABS)-coated cells. Several antisera
were produced in rabbits neonatally "toler-
ized" against normal human lymphocytes
and in adult animals previously injected
with cyclophosphamnide and splenic lyin-
phocytes. The antisera were absorbed with
pooled cadaver spleen and tested against paim-ed
inyeloblasts and PHA-stimiulated autologous
remission lymphocytes. Removal of activity
against spleniic lymphocytes produced complete
loss of anti-iyieloblastic activity in most anti-
sera. The riesidual activity presemit againstmyelo-
blasts in some antisera was due to putativxe cycle-
associated antigens and to myeloid differentia-
tion antigen. Normal marrows% was able to remove
this residual activity. It is concluded that leui-
kaeinic myeloblasts possess essentially normal
antigens and that tumour-specific antigens
cominon to leukaemic myeloblasts, if present on
these cells, are either nion-immuinogenic in the
animals studied, or, if immunogenic, their
presence is below the level of resolution of the
assays uised.
ALLOANTIGEN- UNRESPONSIVE
ALLOGENEIC LYMPHOCYTES FAIL TO
RESPOND TO ACUTE LEUKAEMIC
CELLS WITH AUTOLOGOUS-LYMPHO-
CYTE ACTIVATING-DETERMINANTS.
.J. C. RIDNNWAY, G. M. TAYLOR, P. T. KLOIJDA and
R. HARRIS, Dept. of Medical Genetics, Univ. of
Manchester, St .Mlary's Hospital, _Manchester.
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Leulcoc5ytes froim- certaijo acuite myeNId leukae-
mic (AMIL) patients with acuite disease stiinmulate
proliferation of autologous reinission lympho-
cytes in vitro. Hitherto, it has not been possible
to distinguiish responses to this antigen from
spontaneous lymphocyte proliferation. How-ever,
remission- lymphocytes in which spontaneouis
proliferative capacity was depressed wNith 5-
bromo-2 deoxynridinie (BUdR) retained their
responsiveness to autologouis AML cells. This
suiggests that leukaemic cells ma,y indeed possess
some form of 'leukaemia antigen".
For suich "leuikaemia antigen" to have thera-
peutic significance it shouild stimulate allogeneic
lymphocytes. Though AMIL cells from onie pa-
tient stimulated allogeneic lymphocytes in
primary mixed cell cultture, they failed to
stimullate when the allogeneic lymphocytes were
rendered unresponsive, with BUdR, to HLA-D
antigens on remissionlymphocytes from the same
patient. This couild mean that responses to
"leukaeinia antigen" involved lymphocytes re-
acting with normial HLA-D antigenis, suggesting
that "letikaemia antigen" is itself a modified
form all HLA-D, or that lymphocyte activxation
by 'leuikaemia antigen" is restricted by the
major histocoinpatibility complex (M1HC) to
leukaemic cells and respondinig lymphocytes
identical for HLA-D haplotypes. These two
alternatives are not muttually exclusive. How-
ever, if MHC restriction operates, severe con-
straints on attempts at "specific" immutno-
stimulation by active imn-munotherapy with allo-
geneic AMIL cells w\Nould apply.
ANALYSIS OF T-CELL FUNCTION IN
SPLEENS FROM HODGKIN'S DISEASE
(HD) PATIENTS AND CONTROLS. D. B.
JONES, S. V. PAYNE and D. H. WVRIGHT. Univ.
Department of Pathology, Southampton M1edical
School, Southambpton General Hospital.
Previous lymphocyte-marker studies froIn
this laboratory (Payne et al., 1976, Clin. Eap1.
Immunol., 24, 280) have described a substantial
proliferation of immunoblasts in HD spleens
prior to histological evidence of tumouir in-
volvemnent. M\ore recently, de Soiusa et al. (1977,
Clin. Exp. Immunol., 27, 143) have claimed the
sequestration of T lymphocytes in the spleen as
part of the pathogenesis of HD. With these ob-
servations in mind, we wish to report results
from a stuidy of lymphocyte function in cell pre-
parations froin HD spleens. M\itogen-inducible
cytotoxicity directed against human lymphoid
targets was measured in a 4 h 51Cr-release assay.
A particular problem in this assay was non-
specific killing, which was identified as beinig due
to foetal bovine serum activation of T lympho-
cytes. This activity w-as absent from cells induced
in human AB serum. In this system Con-A was
more efficient than PHA in inducing cytotoxic
effector cells, anid T-depleted preparations wNere
always inactive. Cytotoxicity iniduced in 6 HD
spleen-cell preparations was not observed to vary
predictably from that induced in control
splenic lyinphocytes. T-cell helper fuinctioln
assayed by PWVMAI stimnulation of Ig production
was normal in 2 HD-involved spleens studied.
In two HD-uninvolved spleens, PWMI induced
ninimal Ig production ovem- background. In one
of these, this appeared to be due to defective
B-cell ftunction, since patients' T cells gave a
normal help to allogeneic normal B cells. The
heterogeneity in T-cell fuinction observed in HD
may indicate individual variation in response in
this disease, or that sampling occurred atXvarying
times in a progressive disease process.
HOST CELLS IN HUMAN BREAST
TUMOURS. A. HOWELL, A. SHAALA and N. H.
LING, Departments of Mledicine and Experinmental
P'athology, IUniv. of Birmtinghamt.
As part of a project to assess the prognostic
significance of subpopuilations of host cells,
human breast tutmours w%ere enzymically dis-
aggregated and surface-marker charactem-istics
ofinfiltrating cells assessed. In 10 tumours where
the cell recovery determined by DNA estimation
wkas 56% (range 44-87%), lyinphocytes repre-
sented 9-4o of the popuilation (range 1-8 20 9
predominantly small lyinphocytes) and phago-
cytic cells assessed by latex ingestionrepresented
4-1% (range 1-3-8-0). In a fuirther 26 tumoumrs
where lymphocyte viability exceeded 80%o there
wNere 52% T cells (21-81), 17% B cells (3-36),
15% Fc receptor bearing lymnphocytes (2-52)
and 29% nuill cells (0-60). Similar propor-tions
of cell types were found in 5 benign tumnours
(total lymphocytes 15%, phagocytic cells 3-50,
T 58%o of lymphocytes and B 15% of lympho-
cytes). The mean values for each lymphocyte
population in malignant and benign tuimours are
similar to the means for suibpopulations of lym-
phocytes fouind in peripheral blood, but 7 mnalig-
nant tumourls had T cells below the range, and
4 tumouirs had B cells above the range for peri-
pheral blood. The mean values for subclasses of
B lymphocytes according to surface imnmnluno-
globulins xwere IgA 40o, IgD 50o, IgG 6% and
IgM 7%. In any indiv%idual tumour, one, 2 or
occasionally 3 subclasses couild be absent. The
possible prognostic importance of selection of
subtypes or subclasses of lymphocytes within
tumnouirs is being assessed in a follow-np stuidy.
STEREOSELECTIVE METABOLISM OF
THE OPTICAL ISOMERS OF CYCLO-
PHOSPHAMIDE. P. J. Cox, P. B. FARMER,
A. B. FOSTER and MA1. JARMAN (introdUced by
D. E. V. WILMAN), Chester Beatty Research
Institute (Institute of Cancer Research), London.
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Cyclophosphamide {CP, [bis(2-chloroethyl)-
amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-
oxide } is chiral at phosphorus and thus exists as
enantiomers (optical isomers). Against the mur-
ine ADJ/PC6 transplantable solid tumour, the
(-)-isomer has twice the therapeutic effect of
the (+ )-form. CP is initially ring-hydroxylated,
4-hydroxycyclophosphamide being the only
major metabolite when washed liver microsomes
are used. This transformation was studied by
following substrate disappearance, using stable
isotope dilution-mass spectrometry. Substrates
were pseudoracemates composed of 1:1 mixtures
of (-)-CP-do: (+)-CP-d4 or (+)-CP-do: (-)-CP-
d4, for which deuterium atoms were located in
the chloroethyl groups.
A small degree of substrate selectivity was
showvn by rat liver microsomes, the (-)-CP
being metabolized -10°% faster than the (+)-
CP. This preference was reversed with mouse
liver microsomes. However, rabbit tissue was
markedly stereoselective for (-)-CP, the initial
rate of metabolism and extent of substrate dis-
appearance being >3 x that of (+)-CP.
Secondary oxidation in vivo oftheenantiomers
of 4-hydroxy-CP by mice showed marked sub-
strate stereoselectivity in the formation of 4-
ketocyclophosphamide, but not for the major
metabolite, carboxyphosphamide. The lower
therapeutic efficiency of (+ )-CP may be associ-
ated with the more abundant formation of these
deactivation metabolites, particularly 4-keto CP,
from the (+ )-isomer.
AN INVESTIGATION INTO THE CON-
FORMATION AND BASE SEQUENC-
ING OF DNA FROM YOSHIDA TU-
MOURS SENSITIVE AND RESISTANT
TO METHYLENE DIMETHANE SUL-
PHONATE (MDMS). D. G. POPPITT and
B. WV. Fox, Paterson Laboratories, Christie Hos-
pital and Holt Radium Institute, Manchester.
An unusual effect of the alkylating agent
methylene dimethanesulphonate (MDAIS) with
DNA has been a GC-dependent increase in a
pretransitional hypochromism. The irreversi-
bility of this effect suggests that the agent be-
comes associated with the DNA, but not by
initially interacting covalently, which causes the
strands to separate spontaneously. Such regions
could be observed by the cell repair systems as
damaged. We have previously shown that the
MDMS-resistant line has an increased capacity
to repair damage due to the drug, as well as
having a template activity which is less sensitive
to the same drug. We have now examined the
DNA from both these cell lines, and differences
in the conformation and base sequencing have
been found, by physico-chemical and DNA-
hybridization techniques. There is a 15-16%





TORY ACTIVITY. G. F. KOLAR, T. A.
CONNORS* and P. M. GODDARDt, German Cancer
Research Centre, Heidelberg, F.R.G., *MRC
Laboratories, Carshalton, Surrey and tChester
Beatty Research Institute, London.
The mechanism by which 3,3-dimethyltria-
zenobenzenes inhibit tumours is not clear, but it
does depend on their metabolic conversion to




listed according to their increasing activity
against TLX5 lymphoma, revealed that progres-
sive ring-chlorination leads to (a) retarded meta-
bolite excretion, (b) altered hydroxylation pat-
tern, (c) decreased formation of anilines but (d)
increased excretion of metabolites with intact
diazoamino structure (Kolar and Schlesinger,
1976, Chemotherapy, 8, 91). Triazene metabolites
were converted into the corresponding 4-arene-
azo-N-ethyl-l-naphthylamines which were iden-
tified. 1-(2,4,6-Trichlorophenyl)-3,3-dimethyl-
triazene (IST 79%) did not yield any ring-
conjugated metabolites, but was excreted as a
glucuronoside conjugated through the terminal
dimethylamino group (8-10%). The metabolite
was isolated by adsorption on anionic and catio-
nic exchangers and purified by gel filtration on
Sephadex. Acid hydrolysis liberated glucuronic
acid and formaldehyde which indicated the
presence of a masked N-methylol group. It is
conceivable that this metabolite represents a
stabilized transport form of the activated tria-
zene. Chemical and spectroscopic evidence for
the proposed structure and for the biological
function of the metabolite will be presented.
1 - ARYL - 3 - HYDROXYMETHYL - 3 -
METHYLTRIAZENES: NEW CYTO-
TOXIC DERIVATIVES OF TRIAZENES.
J. A. HICKMAN, A. GESCHER, M. F. G. STEVENS,
K. VAUGHAN and R. SIMMONDS, Cancer Chemo-
therapy Group, Department of Pharmacy, Univ.
of Aston in Birmingham.
1-Aryl-3,3-dimethyltriazenes are selective cy-
totoxic agents with a broad spectrum ofaotivity
against animal tumours (Connors and -Hare,
1975, Biochem. Pharmacol., 24, 2133). It has
been proposed that N-demethylation to N-
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monomethyltriazenes is essential forcytotoxicity
(Connors et at., 1975, Biochem. Pharmacol., 25,
241). However, we have shown that a typical
monomethyltriazene, 1-methyl-3-p-tolyltria-
zene, although cytotoxic, is not selective (Hick-
man and Vaughan, Br. J. Cancer, in press). N-
Demethylation of N,N-dimethyltriazenes has
been suggested to occur via the generation of a
hydroxymethyl intermediate, which then loses
formaldehyde (Preussmann et al., 1969, Bio-
chem. Pharmacol., 18, 1). We now report the
preparation of 1-aryl-3-hydroxymethyl-3-me-
thyltriazenes which were previously considered
to be highly unstable intermediates. These com-
pounds are cytotoxic in vitro, unlike their pro-
genitors the dimethyltriazenes, and have acti-
vity in vivo against the TLX5 lymphoma, com-
parable to the dimethyltriazenes. Under physio-
logical conditions the hydroxymethyltriazenes
liberate formaldehyde and it is considered that,
as in studies on the mechanism of action of
hexamethyl-melamine (Connors and Rutty,
1977, Biochem. Pharmacol., 26, 2385), this might
be importanit in explaining the selective cyto-
toxicit-y of the triazetnes.
METHYLMELAMINES: DEMETHYLA-
TION AND ANTITUMOUR ACTIVITY.
C. J. RUTTY and K. R. HARRAP, Department of
Biochemical Pharmacology, Institute of Cancer
Research, London.
The structure-activity relationships of a series
of derivatives of hexamethylmelamine (HTMM)
have been studied using a mouse plasma-cell
tumour (PC6) and a human lung-tumour xeno-
graft (P246). A correlation between the ability
of the methylmelamines to undergo demethyla-
tion in vitro and their antitumour activity in
vivo has been established. Three derivatives,
namely, pentamethylmelamine (PMM) penta-
methylmonomethylolmelamine, and trimethyl-
olmnelamine have shown marked antitumour
activity. The cytotoxicity of HMM to TLX/5
lymphoma cells in vitro depends on microsomal
activation, whereas PMM-methylol is toxic per
se. The toxicity in both cases can be almost com-
pletely reversed by pretreatment ofthe cellswith
semicarbazide, suggesting that formaldehyde is
the cytotoxic agent. HMM and PMM inhibit the
synthesis of DNA and RNA by TLX/5 cells,
which inhibition can be increased by microsomal
activation, and reversed with semicarbazide.
The two methylols, at lower concentration, cause
almost complete inhibition of nucleic-acid syn-
thesis, an effect which issharedbyformaldehyde.
It is possible to protect selectively against the
PMM-methylol inhibition of pyrimidine deoxy-
ribonucleoside precuirsor incorporation with
semicarbazide. There appear to be two sites of
action: one due to formaldehyde, and the other
to the intact melamine nucleuis.
ALKYLATING AGENTS AND NUCLEO-
SOME INTEGRITY. R. WILKINsON and
K. R. HARRAP, Dept. Biochemical Pharmacology,
Institute of Cancer Research, Sutton, Surrey.
Chlorambucil, melphalan and cyclophospha-
mide induce loss of heterochromatin structure
in alkylating-agent-sensitive tumour lines (Yo-
shida, 'Walker). This effect is not seen in resistant
lines of these tumours. We wish to report here
that the basic structural component of chroma-
tin, the nucleosome, appears unaffected by these
treatments. This observation is based on the
nucleotide fragmentation patterns produced by
micrococcal nuclease digestions of whole nuclei,
wAhich demonstrate the presence of a repeating
unit of 200 nucleotides. Further evidence is de-
rived from studies on the chromatin enzyme
poly-ADP-ribose polymerase, which isassociated
with intact nucleosome oligomers (1977, Bio-
chemistry, 16, 506) and possibly with DNA re-
pair (1977, Cancer Res., 37, 3006). The activity
of this enzyme in sensitive cells is unaffected by
treatment with alkylating agents, though in
resistant cells recovering from damage by
alkylating agents, the activity is considerably
enhanced.
It would appear, therefore, that alkylating
agents affect the tertiary structure of the
chromatin and not nuicleosome integrity.
THE COMPARATIVE PHARMACOKI-
NETICS OF PREDNIMUSTINE AND
CHLORAMBUCIL. H. NEWELL, R. WXILKIN-
SON and K. R. HARRAP, Dept. Biochemical Phar-
macology, Institute of Cancer Research, Sutton,
Surrey.
MVe have previously shown, in the rat, that
the toxicity of chlorambucil can be reduced,
without compromising its antitumour effective-
ness, ifit is given in the form ofthe prednisolone
ester, prednimustine (1974, Eur. J. Cancer, 13,
873). The pharmacokinetics of chlorambucil and
prednimustine were compared, in the rat, in an
attempt to explain this lower toxicity. Follow-
ing its s.c. administration, plasma levels of
chlorambucil and its major metabolite phenyl
acetic mustard, each decayed with half-lives of
2-1 h. On the other hand, levels of chlorambucil
and phenyl acetic mustard, produced from an
equirvalent dose ofprednimuistine (also given s.c.)
are maintained relatively constant for -40 h at
1/20th the peak level achieved fIom chlorain-
bucil alone; no unhydrolysed prednimnustinle
w-as detected in the plasma. The lower toxicity
of prednimustine could be simulated in part
by low-dose repeated adrninistration of chlor-
ambticil aloine, with no loss of antitumnouir
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activity. In man, oral chlorambucil adminis-
tration produced detectable plasma levels
of both chlorambucil and its inetabolite
phenyl acetic mustard, which persisted for 4 h.
Following an equivalent dose of prednimustine,
no chlorambucil of phenyl acetic mustard was
detectable. These data indicate that the anti-
tumour selectivity of alkylating agents can be
increased by using a multiple low-dose regimen.
A re-evaluiation of current single, high-dose
alkylating-agent therapy in man may therefore
be indicated.
THE EFFECT OF ANAESTHETICS ON
MELPHALAN CYTOTOXICITY. J. H.
PEACOCK and T. C. STEPHENS, Institute of Cancer
Research, Sutton, Surrey.
We have studied the influence of anaesthetics
on tumour cell kill by the cytotoxic agent Mel-
phalan. B16 melanoma was treated in vivo and
cell survival was measured in vitro using a colony
forming assay. Three anaesthetics were em-
ployed, Saffan, Nembuital and Hypnorm. When
Saffan (90 mg/kg) was administered 20 min be-
fore Melphalan (2 to 20 mg/kg) there was a sig-
nificant increase in the cell-killing effect of this
agent. This was not found with Nernbutal or
Hypnorm. The effect of varying the dose and
tirne of administration of Saffan relative to a
fixed dose of Melphalan (7.5 mg/kg) was exam-
ined. The enhancement of Melphalan cell kill by
Saffan increased as the dose of Saffan was raised
(15-150 ing/kg). The optimum time of adminis-
tration of Saffan (90 mg/kg) for maximum en-
hancement of cell kill was 15-30 mnin before
Melphalan. When Saffan was administered after
Melphalan no enhancement was seen.
It has been suggested that steroid hormones
may modulate the effect of Melphalan, and since
Saffan is a steroid, this may accoutnt for the
observed effect.
THE PHARMACOKINETICS AND META-
BOLISM OF CHLORAMBUCIL IN PA-
TIENTS WITH CHRONIC LYMPHOCY-
TIC LEUKAEMIA. A. MCLEAN, Dept. of
Chemistry, Univ. of Surrey, Cuildford, H.
WrOODs and D. CATOVSKY, MRC Leukaenmia
Unit, Hammersmith Hospital.
Five patients have been stuidied after oral
administration of 14C-chlorambucil in doses of
15-30 mg/M2. Absorption has been found to be
consistently rapid, and the maximum concentra-
tion of plasma radioactivity/ml varied between
50 and 70 min. After i.v. administration the rate
of elimination of radioactivity from the plasma
has been fouind to be rapid. Urinary excretion
was studied Up to 3 days after drtug adminiistra-
tion, and total radioactivity in the urine varied
between 28 and 68%. In all patients studied, the
bulk of urinary excretion occurred during the
first 24 h.
Chromatographic analysis of blood extracts
indicates that the humanmetabolism ofchloram-
bucil follows an analogous course to the reported
animal metabolism (A. McLean et al., 1976,
Biochem. Pharmacol., 25, 2331). In all patients
studied :-oxidation ofthe butyric acid side chain
of chlorambucil was observed. Analysis of urine
samples obtained shortly after oral and i.v. ad-
ministration indicated the absence of chlorain-
bucil and the presence of traces of metabolites
chromatographicallyindistinguishable from bis
and mono 2-chlorethyl derivatives of p-amino-
phenyl acetic acid.
The information obtained from the plasma-
radioactivity measurements, coupled to the
analytical data, indicates that the oral route of
administration of chlorambucil is not disadvan-
tageous with respect to the iv. route. The rate
ofmetabolism is sufficient to allowthemetabolite
material to contribute significantly to the acti-
vity of the drug.
A FLOW CYTOFLUORIMETRIC ASSAY
FOR CELLULAR ESTERASES IN POPU-
LATIONS OF SINGLE CELLS. S. H.
CHAMBERS, P. WORKMAN, J. V. WATSON and
N. M. BLEEHEN, MRC Clinical Oncology Unit,
The Medical School, Hills Road, Cambridge.
A flow cytofluorimeter has been linked directly
to a PDP 11/40 computer in order to measure
the rate of hydrolysis of fluorogenic substrates
in wvhole cells.
Cellular esterases have been assayed in log
and plateau-phase EMT6 cells using fluoresceiri
diacetate as substrate.
At the maximum substrate concentration of
2-0 ,A 28-day-old plateau-phase cells showed a
5-fold increase in enzyme activity, compared
with 3-day-old log-phase cells. Over the samne
time interval, plating efficiency fell from 95 to
50%.
Data obtained with whole homogenates using
standard spectrofluorimetric assay gave normal
Michaelis-Menten kinetics. That obtained froin
whole cells in the same instrumernt, showed
marked deviation from normal kinetic beha-
viour and agreed w-ith the curves obtained from
whole cells in the cytoflumorimeter.
Inhibition of esterase activity by chloram-
buicil was less in whole cells than in homogenates
but inhibition by nitrogen mustard wvas approxi-
mately equal in the two preparations. Again,
data from whole cells using standard spectro
fluorimetric methods agreed with the compiuter-
linked cytofluiorimetric anialysis.
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EFFECTOR CELLS AT THE SITE OF
IMMUNOTHERAPY-INDUCED TU-
MOUR REGRESSION. R. A. ROBINS, D. G.
HOPPER and R. W. BALDWIN, Cancer Research
Camnpaign Laboratories, Univ. of Nottinghamt.
A inethylcholanthrene-induced rat sarcoma
(Mc7) when transplanted in syngeneic recipients,
was shown to be infiltrated by macrophages
(,20%) and lymphoid cells (7-8%); there was
little change in the proportions of host cells
during progressive tumour growth. Small ttu-
mours developed then regressed in rats given
active immtunotherapy consisting of an s.c. in-
jection of sarcoma cells in admixture with BCG
at a contralateral s.c. site. In these regressor
tumours, a high proportion of lymphoid cells
was present at the onset of tumour rejection.
Effector-cell preparations enriched for tumour-
derived lymphoid cells were prepared frorn re-
gressor tumours by velocity sedimentation and
nylon fibre column filtration. When tested in a
75Se-Selenomethionine microcytotoxicity assay,
these tumour-derived effector cells were cyto-
toxic for cultured tuinouir cells. A component of
this cytotoxic activity was apparently specific
for Sarcoma Mc7. Tumour-derived effector cells
have also been prepared from progressively
growing AMc7 ttumours. Interestingly, prelimin-
ary experiments indicate that lymphoid cells
from progressor tumours may be equally cyto-
toxic to those from regressor tumouirs. These
findings indicate that lymphoid cell accuintla-
tion in the tumour is iinpoi-tant for ttumouir
rejection .
STUDIES ON TWO TUMOUR IMMUNO-
THERAPY MODELS: INDUCTION OF
SPECIFIC SYSTEMIC IMMUNITY AND
IMMUNOSTIMULATION BY DERMAL
APPLICATION OF ADJUVANT. N. WILL-
MOTT, E. B. AUSTIN, M. V. PIMM and R. WV.
BALDW'IN, Cancer Research Canmpaign Labora-
tories, U.niv. of Nottinghami.
Two immunnotherapeutic modalities have been
developed for treating s.c. challenge inocula of
MICA-induced sarcomas in the rat, and an assess-
inent made of their efficiency in treating post-
surgical lymph node metastasis from a sponta-
neouis mammary carcinoina Sp4 (Greager and
Baldwin, 1978, Cancer Res., 38, 69). S.c. injec-
tioIn of 230 ,ug ofC. parvunt (WVellcome, CN6134)
mixed with viable or irradiated tumouir cells
(2 x 106) elicited specific systemic immunity
capable of controllirig a distant s.c. challenge
(106 cells) of an immulnogenic rat sarcoina
injected on the same day as the vaccine. Alter-
natively, repeated administiration of BCG
(Pasteur F) by the dermal rouite, starting on
the same day as turmourl challenge, was able
to conitm-ol ani s.e. inoctlthimii of a different
immunogenic rat sarcoma (105 cells). However,
in preliminary experiments with a spontaneouis
mammary carcinoma, designed to treat lymph-
node metastasis appearing after removal of the
primarv tuimour, it was found that immuno-
therapeutic regimes effective at treating s.c.
inocula of immunogenic MCA-induced tumours
were not effective at treating lymphnode
metastasis.
SEQUENTIAL MONITORING OF CIR-
CULATING IMMUNE COMPLEXES IN
TUMOUR-BEARING RATS AND RATS
GIVEN SUCCESSFUL CHEMOTHERAPY
OR ACTIVE IMMUNOTHERAPY. P. J.
AMCLAUGHLIN, K. H6FFKEN, M. R. PRICE, V. E.
PRESTON and R. W. BALDWIN, Cancer Research
Campaign Laboratories, Univ. of NTottingham.
Circulating immune complexes were measured
in rats bearing s.c. transplanted 3-methylcho-
lanthrene induced sarcomas using the 1251-
Clq-binding inhibition assay of Fletcher and Lin
(1977, J. Immunol. Methods, 15, 39). Sera from
rats receiving chemotherapy or active immtuno-
therapy (BCG+tumour cells) were also sequen-
tially monitored for immtlne complexes.
Writh animals bearing progressively growing
tumours, Clq-binding activity was detected in
the early phase of tumour growth, but, after
reaching a maximum, decreased in spite of
tumrour progression. This profile of Clq binding
was not, however, observed when tumour
growth was controlled bychemotherapy oractive
iinmunotherapy. In these cases no significant
levels of immune complexes were detectable. In
contrast, animals failing to respond to therapy
had immunre-complex levels similar to those of
tumour-beaiing rats.
Studies to characterize the circulating immune
complexes have indicated that they are, at least
in part, ofa tumour-specific nature, and that the
apparent fall in immune-complex levels in late
stages of tumour growth is due to changes inl
antigen-antibody ratio, and a shift from com-
plement-fixing to non-complement-fixing anti-
bodies.
The present findings suggest that measure-
ment of Clq-binding seruin factors may provide
a usefuil method for monitoring the growth and
burden of experimental animal tumours.
THE GROWTH OF HUMAN URINARY
BLADDER CARCINOMAS, AS PULMON-
ARY NODULES, FOLLOWING I.V. IN-
JECTION OF TUMOUR CELLS INTO
IMMUNE-DEPRIVED MICE. K. COOPER,
M. 0. SYMES and C. R. TRIBE, Departmtent of
Surgery and Pathology, UJniv. of Bristol.
The growth of human bladder carcinomas, in
iilLmunIe-deprived mice, has been reported
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(Kelly et al., 1975, Br. J. Cancer, 31, 237; Franks
et al., 1976, Br. J. Cancer, 33, 112). CBA-PC
mice were subject to thymectomy at 6-10 weeks
of age. Two to 16 weeks thereafter the nmice re-
ceived 900 rad whole-body irradiation. Haemo-
poiesis was restored by i.v. injection of 5 x 106
CBA marrow cells (pre-incubated in immuno-
suppressive anti-thymocyte serum) within 6 h
of irradiation.
The mice were each challenged 4 weeks after
irradiation with 106 cells from a suspension made
from 1 of4 bladder carcinomas. The tumour cells
were injected i.v. to facilitate the development
of pulmonary tumour nodules. The mice were
killed 4 weeks after injection of tumour cells,
their lungs fixed in Bouin's fluid and the number
of nodules counted by eye.
Eight or 16 weeks were the optimum intervals
between thymectomy andirradiation to promote
the development of pulmonary nodules. At the
8-week thymectomy-to-irradiation intervalthere
was a good correlation (Rank Difference Co-
efficient=0-7) between the number of nodules
formed and the malignancy of the tumour
obtained from the patient, as assessed histo-
logically.
DETECTION OF NORMAL CELL KILL-
ING AGAINST RAT TUMOUR CELLS:
IN VITRO AND IN VIVO STUDIES. R. C.
REES* and C. G. BROOKSt, *Dept. of Virology,
Univ. of Sheffield Medical School and tCancer
Research Campaign Laboratories, Univ. of
Nottingham.
Lymphnode cells (LNC),preparedfromnormal
rats, could either enhance or inhibit the in vitro
growth of tumour cells derived from syngeneic
chemically induced sarcomas and hepatomas.
Fractionation of LNC revealed that the growth-
enhancing activity predominated in the cell
population eluted from nylon-wool columns,
whereas the growth-inhibitory activity was
largely a property of nylon-wool-adherent cells.
When column-fractionated LNC were cultured,
in the absence of tumour cells, the resulting cell-
free supernatants caused the respective inhibi-
tion or enhancement of tumour-cell growth pre-
viously shown by whole LNC. The tumour-
growth-inhibitory material was heat stable at
56°C, and was present in the supernatant after
1 h ofculture, whereas growth enhancement was
only observed in supernatants after prolonged
in vitro LNC culture.
Experiments performed in vivo, using nylon-
wool-column-enriched LNC fractions indicate
that LNC sub-populations may cause tumour-
growth inhibition or enhancement. Normal rat
LNC, which showed NK activity towards target
cells in vitro, were shown to retard the develop-
ment of tumours when adoptively transferred,
in mixed inoculum with tumour cells, into
syngeneic recipients.
The results obtained suggest that apparently
uneducated lymphoid cells are involved in con-
trolling tumour growth, and that soluble factors
released from these cells contribute to the
observed effects.
EFFECT OF INTRAVENOUS CORYNE-
BACTERIUM PARVUM (CP) ON CYTO-
TOXIC EFFECTOR CELLS IN THE RAT.
E. C. PURVES, Dept. of Experimental Pathology,
St Mary's Hospital Medical School, London.
We looked at the effect of i.v. CP on the non-
specific killer cell (NK) activity (Ono et al., 1977,
Nature, 266, 546) and the antibody-dependent
cell-mediated cytotoxic (ADCMC) activity
(McDonald and Bonnard, 1975, Scand. J.
Immunol., 4, 129) of cells from rat blood and
spleen, before and after removal ofmacrophages
with iron powder.
CP treatment was followed by a large increase
in NK activity. After removal of phagocytes,
the actual degree of cytotoxicity was reduced,
but the difference between cells from treated and
untreated rats was increased, showing that CP
increases the activity of the NK cell, and that
macrophages can act as effector cells ofthis type.
ADCMC activity was, on the other hand, only
slightly increased in cell suspensions from CP-
treated rats, but removal of phagocytes caused
an increase in this type of cytotoxicity.
Again the increase was greater for cells from
CP-treated rats. Thus macrophages can inhibit
ADCMC assays, and CP treatment enhances the
activity of both phagocytic and non-phagocytic
effector cells.
INTRAPLEURAL (I.PL.) INJECTION OF
C. PARVUM (CP). M. T. SCOTT and J.
DECKER, The Wellcome Research Laboratories,
Beckenham, Kent.
In collaboration with the Ludwig lung-cancer
trial (EORTC Newsletter, 55, May 1977) the
characteristics of CP injected i.pl. in mice, and
its effectiveness against experimental lung-
associated tumours have beeninvestigated. After
i.pl. injection most ofthe CP was confined to the
pleural and mediastinal spaces, the pleural
phagocytes and mediastinal lymph nodes being
heavily labelled. None was found within the
lung. Some CP did, however, leak systemically,
and was found in the spleen and liver. Spleno-
megaly 14 days after i.pl. CP was similar to that
after i.v. injection. I.pl. CP was capable of en-
gaging both immunological-specific (lymphocyte
mediated) and non-specific (activated-macro-
phage mediated) antitumour mechanisms. (a)
Non-specific: a large proportion of the cells pres-
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ent in pleural washouts 4 days after i.pl. CP
were activated macrophages which non-speci-
fically inhibited the proliferation oftumour cells
in vitro. (b) Specific: local interaction ofCP with
tumour antigen in the pleural cavity (i.pl. CP
mixed with irradiated tumour cells) conferred
strong, specific, systemic immunity against sub-
sequent live tumour-cell challenge, whereas CP
or tumour antigen alone are without effect. The
immunity was detectable in cell suspensions pre-
pared from the mediastinal node. L.pl. CP has
been compared with i.v. CP for its effect against
tumours growing either in the lung or in the
pleural cavity. L.pl. CP was more effective than
i.v. CP against tumour growing in the pleural
cavity. L.v. CP was more effective than i.pl. CP
in reducing the number of lung metastases re-
sulting from i.v. injection of tumour cells, but
survival of mice was consistently longer after
I.pl. CP.
INTRAVENOUS BCG THERAPY OF
MAMMARY CARCINOMA IN BITCHES
AFTER SURGICAL EXCISION OF THE
PRIMARY TUMOUR. N. T. GORMAN, D. E.
BOSTOCK and L. N. OWEN, Dept. Clinical
Veterinary Medicine, Univ. of Cambridge.
Thirty-four bitches with defined histological
forms ofmammary carcinoma were studied post-
mastectomy for over 100 weeks. They were
randomized into 3 groups:
(a) no further treatment (11)
(b) placebo treatment (10)
(c) i.v. BCG therapy (13).
The median survival time of the control
groups was 24 weeks, whereasthatforthetreated
groups was 100 weeks. This was significantly
different (P < 0.05) as calculated by the Chi-
square test.
EFFECTS OF C. PARVUM IN DOGS
AND A STUDY OF ITS DISTRIBUTION
FOLLOWING INTRAVENOUS INJEC-
TION. J. C. M. LEWIS, L. N. OWEN, D. R.
MORGAN and N. T. GORMAN, Dept. of Clinical
Veterinary Medicine, Univ. of Cambridge.
Studies were made in dogs to determine the
distribution of Corynebacterium parvum (CP)
after its i.v. administration, its pathological
effects and the possible cytotoxicity of alveolar
macrophages thus stimulated.
The distribution of CP was followed using
1125 and FITC labelling techniques previously
described by Scott and Milas (1977, Cancer Res.,
37, 1673). Alveolar macrophage cytotoxicity was
studied by release of isotope from Cr51-labelled
allogeneic target cells.
Persistence of labelled CP was most marked
in the liver, spleen and lungs, but was eliminated
13
faster from the latter than from the other two
organs. The pattern of distribution was similar
to that of the mouse (Scott and Milas, 1977,
Cancer Res., 37, 1073 and Sadler et al., 1977, Br.
J. Cancer, 35, 357) but elimination was faster.
Gross pathological changes following i.v. CP
were few and histological changes restricted to
small granuloma in liver and lungs. C. parvum
vaccine given s.c. or i.m. produced local reac-
tions, but not if diluted.
Alveolar macrophages from dogs injected with
CP exhibited some significant target-cell cyto-
lysis when compared with macrophages from
normal dogs.
Given that i.v. CP follows a similar pattern in
dogs and mice, it would appear likely that a
similar distribution would occur in man. It
would be advantageous to use i.v. CP if it can
be demonstrated as being as effective as BCG
in delaying metastasis in the dog.
INTRA-PLEURAL BCG IN OPERABLE
LUNG CANCER. P. B. ILES, D. F. SHORE,
R. W. BALDWIN and M. J. S. LANGMAN, Depts.
of Therapeutics and Cancer Research, Univ.
of Nottingham, and Thoracic Surgery, United
Sheffteld Hospitals.
Following the report of McKneally et al.
(1976, Lancet, i, 377) ofthe benefit ofBCG (Tice)
given intra-pleurally to patients after resection
for lung cancer, we instituted a controlled,
prospective randomized study of intra-pleural
Glaxo BCG in May, 1976.
Patients were randomized to receive (a) Glaxo
BCG, 107 viable organisms following surgery,
then 8 weeks' Isoniazid 300 mg daily starting 2
weeks later; or (b) Placebo (Lactose) tablets for
8 weeks commencing 21 weeks after surgery.
Ninety-two patients have entered the study, 77
having non-anaplastic cancer. Six ofthe 38 BCG-
treated and 9 of the 39 control non-anaplastic
cancer patients have died, giving cumulative 18-
month survival rates of 77% and 63% respec-
tively. This difference is not significant. Two of
the 22 Stage I non-anaplastic BCG patients have
died compared with 7 of 23 controls, and this
trend reaches significance (X2=4-195, P < 0-05,
Log rank test). Approximately half of the pa-
tients with anaplastic ca. have died, irrespective
ofstaging or treatment. Halfofthe BCG-treated
patients had a febrile reaction and this was
independent of heaf-test response; other com-
plications were similar in both groups.
The limited benefit from Glaxo BCG may be
related to the lower incidence and duration of
febrile response compared to that reported with
Tice BCG, but since 5 of the 11 BCG-treated
patients to die had been febrile other factors may
be important. These data suggest that intra-
pleural Glaxo BCG in the dosage used may have
enhanced non-anaplastic cancer patients' sur-
vival.
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POSTER EXHIBITS
IDENTIFICATION OF THE PROXIMATE
FORM OF THE CARCINOGEN 15,16-
DIHYDRO - 11- METHYLCYCLOPENTA -
[A]PHENANTHREN-17-ONE. M.M. COOMBS,
T. S. BHATT and A. M. KIssONERGHIS, Chemistry
Department, Imperial Cancer Research Fund,
London.
After microsomal activation, the [14C]-car-
cinogen(I) bound to DNA in vitro. Enzymatic
hydrolysis of the DNA, followed by chromato-
graphy on Sephadex LH 20 columns, yielded 2
adduct peaks, A andB,whichelutedaftertheun-
changed nucleosides. Isolation of DNA from
mouse skin treated in vivo with (I), and analysis
as before gave only one adduct peak, chromato-
graphically identical with B. Individual meta-
bolites of (I), also separated on LH 20 columns,
were incubated with the microsomal activating
system and DNA, which was then recovered and
analysed. Adduct B arose from a single metabo-
lite with the polarity of a diol, identified by
chemical reactions employing UV spectroscopy
as the 3,4-dihydro-3,4-dihydroxy derivative of
(I). This is therefore the proximate form of this
carcinogen.
Adduct B had a UV spectrum similar to that
of 1,2,3,4-tetrahydro-(I). The aryl hydrocarbon
hydroxylase inhibitor 7,8-benzoflavone delayed
skin tumour production with (I) (Coombs et al.,
1975, Cancer Res., 35, 305). Moreover, in another
experiment the mean latent periodwasdecreased
from 35 to 22 weeks by administrations of (I)
together with the epoxide-hydrase inhibitor
1,1,1-trichloropropane oxide. Both these obser-
vations indicate that the reactive metabolite is
an aryl oxide. It is therefore suggested that the
ultimate form ofthis carcinogen is a 3,4-diol-1,2-
oxide of (I), analogous to the biologically active
diolepoxide of benz[a]pyrene.
CHANGES IN SURFACE MORPHOLOGY
RELATED TO ETHYL-NITROSOUREA-
INDUCED MALIGNANT TRANSFORMA-
TION OF CULTURED RAT BRAIN
CELLS. J. P. RoSCOE, D. P. WINSLOW and P.
ROWLES, School ofPathology, Middlesex Hospital
Medical School, London.
Cultures of cells clonally derived from either
normal adult rat brain or a culture of a mixed
glioma were studied by scanning electron micro-
scopy. The two normal lines, ARBO C9 and
ARBO ClI, were found to display very little
surface activity. The cells were large, extremely
flat with prominent nuclei and had few microvilli
or ruffles. In contrast, the two tumour lines
A15A5 and A15A10 displayed a striking amount
of surface activity which greatly exceeded that
shown by the normal cells grown and fixed under
identical conditions. These cells were highly con-
densed and possessed large numbers of blebs,
filopodia and pleomorphic microvilli. Cells de-
rived from rat brains transplacentally exposed
to either ethyl-nitrosourea (ENU) or citrate
buffer and cultured at 111-112 days after injec-
tion were also studied. The results here support
our above findings; showing similar differences
in the surface activity of control and tumouri-
genic lines. Preliminary results from one line
suggest that cells exposed to ENU but which had
not yet shown transformed properties such as
growth in agar, tumourigenicity or high fibri-
nolytic activity displayed an intermediate
morphology between control and tumourigenic
lines.
EPIDEMIOLOGICAL STUDY OF THE
MORTALITY OF BRITISH CHEMISTS.
C. E. SEARLE and J. A. H. 'WATERHOUSE, Univ.
of Birmingham Medical School, Birmingham and
B. A. HENMAN, D. BARTLETT and S. MCCOMBIE,
Royal Institute of Chemistry, London.
Chemists are exposed to a wide range of
chemicals during their training and work, but
few epidemiological studies of their health have
been carried out. Members of the American
Chemical Society were reported to have an in-
creased death rate from malignancy relative to
other professional workers (Li etal., 1969,J. Natl.
CancerInst., 43, 1159) the most markedincreases
being in lymphomas and pancreatic tumours.
Respiratory disease and liver cirrhosis were less
common in the chemists. A smaller but more
complete study of Swedish chemists also noted
an increase in deaths from lymphomas (Olin,
1976, Lancet, ii, 916).
A study of British chemists has now been
initiated. Death certificates were obtained for
1332 members of the Royal Institute of Chemis-
try who died in 1965-75 inclusive. Deaths of 291
werefromneoplasms, representing ahigher-than-
expected proportion of all causes of death in the
age-range 36-50. Though analysis of deaths is in
an early stage, it appears that the incidence of
lymphomas may be elevated in RIC members
also.
Relative to the general population there is a
high colon/rectum cancer ratio in the chemists.
However, this is also seen in medical practi-
tioners (Doll and Peto, 1976, Br. Med. J., ii,
1525) suggesting that it is associated with socio-
economic status rather than chemical exposure.
Good records of the occupational histories of
many RIC members offer possibilities of linking
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mortality with chemical exposure. It is hoped to
extend the retrospective study and to initiate a
prospective one.
LUNG-CANCER RISKS IN THE SMOK-
ING OF DIFFERENT TOBACCOS. T. E.
BETTS and L. A. ELSON, Research Laboratories,
Brompton Hospital, London.
Reliance solely on mouse-skin carcinogenicity
tests is not satisfactory in assessing the cancer
risks in smoking different tobaccos.
Although no frankly malignant transforma-
tions have been seen, exposure of rats to the
smoke of different tobaccos can result in patho-
logical effects on the lungs and bronchi, the
extent of which varies with the type of tobacco
smoked.
Groups of rats, reared under minimal disease
conditions, were exposed to the smoke of (A)
Flue-cured, (B) Air-cured and (C) Cigar tobacco.
After 6 weeks' exposure, quantitative measure-
ments were made, post mortem, on formalin-
fixed lung and bronchial tissue. The increase in













(1) with potassium permanganate in aqueous
acetone, or by the Udenfriend method, or by in-
cubation with a rat-liver homogenate in the
presence of an NADPH-generating system,
afforded the ac-oxidized triazene 4-(4-chloro-
phenylazo)morpholin-3-ol (2) together with
R
Cl < N=N-N/O
(1) R = H; (2) R = OH
Cl N-N-N 0O
(3)
traces of 1,3-bis-(4-chlorophenyl)triazene and 4-
chloroaniline. Attempted acetylation of (2) with
acetyl chloride in pyridine led to an elimination
reaction and the formation of the dehydro-
morpholine (3). Although ac-oxidation is assumed
Goblet cells
17 -8±7 * 7
12 - 7±8- 3
2-4±1-3
0 4±0*3
Under these conditions, where inhalation is
obligatory, the smoke of Flue-cured and Air-
cured tobaccos produces more serious patho-
logical changes than does the smoke of Cigar
tobacco.
Possibly some factor not distinguished in the
mouse-skin painting test is removed or modified
in the cigar-tobacco fermentation process.
oc-HYDROXYLATION OF HETEROALI-
CYCLIC TRIAZENES. A. GESCHER, J. A.
HICKMAN and M. F. G. STEVENS, Cancer Chemo-
therapy Group, Dept. Pharmacy, Univ. of Aston
in Birmingham.
Although heteroalicyclic triazenes are, in
general, inactive as antitumour agents, their
chemical properties show similarities to those of
the antitumour aryldimethyltriazenes and the
carcinogenic heteroalicyclic nitrosamines (Ges-
cher et al., 1977, J. Chem. Soc. Perkin Trans., I,
pp. 107 and 2078). A study of the chemical and
metabolic oxidation ofsuch compounds can shed













to be a crucial step in the bio-activation of
triazenes, this is the first report of the isolation
and characterization of an oc-hydroxylated
derivative from the metabolic transformation of
a triazene.
TWO APPROACHES TO SELECTIVE
REVERSAL OF METHOTREXATE
TOXICITY. P. J. DADY, G. A. TAYLOR, A. H.
CALVERT and K. R. HARRAP, Dept. Biochemical
Pharmacology, Institute of Cancer Research,
Sutton, Surrey.
We have shown that L1210-tumour-bearing
DBA2/C57 BL Fl hybrid mice may be rescued
from toxic doses of methotrexate by a combina-
tion of inosine, thymidine and allopurinol.
Animals "rescued" with this purine and pyrimi-
dine combination survived longer than those
"rescued" with folinic acid, indicating enhanced
antitumour activity.
Tissue culture studies have indicated that 5-
methyl tetrahydrofolate may have theoretical
advantages over folinic acid as a rescue agent.
We present some experiments using high-dose
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methotrexate in tumour-bearing animals, which
confirm that "rescue" with 5-methyl tetrahydro-
folate can be more selective than folinic-acid
rescue.
THE PHARMACOKINETICS OF MISO-
NIDAZOLE IN NORMAL AND TUMOUR-
BEARING DOGS. R. A. S. WHITE*, P. WORK-
MAN, L. N. OWEN* and N. M. BLEEHEN, Clinical
Oncology and Radiotherapeutics Unit, Hills Road
and *Dept. of Clinical Veterinary Medicine,
Madingley Road, Cambridge.
The hypoxic cell sensitizer misonidazole (Ro
07-0582) has a much shorter half-life in the
mouse and rat than in man. We therefore studied
the pharmacokinetics of the drug in the dog to
evaluate this species as a model for man.
Levels of misonidazole and its 0-demethyl-
atedmetabolite Ro 05-9963 in plasma and tissues
were estimated by high-performance liquid
chromatography (Workman et al., J. Chromatog.,
in press). In normal dogs the bioavailability of
misonidazole was similar after i.v. and oral ad-
ministration. After oral dosage, peak plasma
concentrations occurred between 2 and 6 h. The
half-life of the drug (4-9 h) was independent of
dose and route ofadministration and was similar
to that in man (4-12 h) (Wiltshire et al., unpub.).
The apparent volume of distribution of misoni-
dazole indicated uniform distribution in body
water. Similar levels of Ro 05-9963 after various
doses of misonidazole indicated possible satura-
tion of demethylating enzyme(s).
In 3 dogs bearing spontaneous tumours, given
150 mg/kg i.v., concentrations in normal tissues,
including brain, were similar to the correspond-
ing plasma concentrations. An exception was the
liver, which was < 10%. Tumour levels reached
80-90% of the corresponding plasma concentra-
tions.
The similarity of these data to those in man
indicate that the dog may be a good model for
the study of misonidazole as a hypoxic cell
sensitizer.
IN VITRO METABOLISM OF CYTOSINE
ARABINOSIDE IN NORMAL AND TU-
MOUR BREAST TISSUE. A. BAXTER, L. M.
CURRIE and J. P. DURHAM, Dept. of Clinical
Oncology, Univ. ofGlasgow, and D. C. SMITH, Div.
of Surgery, Victoria Infirmary, Glasgow.
Significant levels of deoxycytidine kinase, the
enzyme which activates cytosine arabinoside
(Ara-C) have been measured in human breast
tumours and normal breast tissue. A mean
activity of 0.5 u/mg protein was found in 21
tumours and of 0-52 u/mg protein in 9 controls.
Concomitant measurement of cytidine deami-
nase, the enzyme which inactivates Ara-C, yields
a mean tumour value of 1-6 u/mg protein and a
mean normal value of 2-3 u/mg protein. These
levels of kinase activity and the ratios of kinase
to deaminase activity compare very favourably
with data for other human normal andneoplastic
tissues (Ho, 1973, Cancer Res., 33, 2816).
Kinetic studies on the interaction of Ara-C
with these enzymes have been carried out on
paired normal and tumour tissues from 6 pa-
tients. In tumour tissue the kinase displays an
11-fold higher affinity (as determined by Km
measurements) than the deaminase for Ara-C,
while in normal tissue the affinityis 6-foldhigher.
When these data are related to the ratios of the
enzyme activities, the net effect should be acti-
vation of the drug, and suggests a possible use
of Ara-C in the treatment of carcinoma of the
breast. Moreover, these data suggest that activa-
tion ofthe drug will be 3 times higher in tumour
tissue than in control tissue, leading to decreased
toxicity in normal breast tissue.
THE EFFECTS OF HYDROXYUREA (HU)
AND CYTOSINE ARABINOSIDE (ARA-
C) ON JEJUNAL CRYPTS AND ACCES-
SORY SEX ORGANS (ASO) IN THE
MOUSE. M. R. ALISON and N. A. WRIGHT,
Harkness Laboratories, Radcliffe Infirmary,
Oxford.
It has been reported that DNA-synthesizing
cells ofcell renewal systems are more susceptible
to the necrotizing effects of HU than those in
stimulated tissues (Farber and Baserga, 1969,
Cancer Res., 29, 136). ASO epithelial cells are
quiescent, but enter DNA synthesis after a
period of androgen deprivation (3 days) and
testosterone (T) injection. A continuous thymi-
dine-labelling technique revealed that the frac-
tion of proliferating (P) cells in the coagulating
gland (CG) was 30%. Mice were injected with
either Ara-C (400 mg/kg body wt.) or HU (1600
mg/kg body wt.) after 50 h T stimulation. Some
mice received a second injection at a time of
maximum labelling index during the recovery
phase, 10 and 14 h later in the Ara-C and HU-
treated groups respectively. Ara-C and HU were
equally damaging upon crypt cells, 38% of cells
being degenerate after 2-4 h. Crypt column
height was reduced from 23 4±2 2(s.d.)-28-1
+3 cells (range during T stimulation) to 16-5±
1-6 cells 8 h after Ara-C and 18-2±1-5 cells 8 h
after HU. In the ASO, DNA synthesis was simi-
larly inhibited for 6-8 h. Fewer necrotic cells
were observed than expected from labelling in-
dices, but the greater cytocidal effect of Ara-C
was associated with the recruitment of non-
cycling (Q) cells into the P compartment, a
phenomenon of significance in tumour growth
(Gelfant, 1977, Cancer Res., 37, 3845).
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EFFECTS OF MULTIPLE HUMAN-
EQUIVALENT I.V. DOSES OF CORYNE-
BACTERIUM PARVUM IN THE MOUSE.
H. D. MITCHESON, T. E. SADLER and J. E.
CASTRO, Urology and Transplantation Unit,
Royal Postgraduate Medical School, Hammer-
smith Hospital, London.
The aim of this study was to investigate the
effects of multiple human-equivalent i.v. doses
of C. parvum in the mouse, and to compare these
Nvith the response to a single highdose ofvaccine.
The whole-body, liver, spleen and thymus
weights, and antibody titre against C. parvum
were determined.
C. parvum was injected either weekly as a low
dose (70 tLg) or as a single high dose (466 tg).
Both treatments had similar effects on total-
body, liver, spleen and thymus weights. How-
ever multiple low doses caused a higher antibody
titre against C. parvum, 25 log2 after 4 injections
compared with 8 log2 after a single high dose.
The effect of these treatments on the growth
ofprimary Lewis tumour and its metastases was
studied. Multiple low-dose C. parvum treatment
was given both before or after tumour inocula-
tion. These results will be discussed.
UNCONJUGATED DIHYDROTESTO-
STERONE AND TESTOSTERONE LE-
VELS IN SERUM OF PATIENTS WITH
CARCINOMA OF THE PROSTATE. R.
GHANADIAN, C. M. PUAH and E. P. N. O'DONO-
GHUE, Prostate Research Laboratory, Royal Post-
graduate Medical School and Institute of Urology,
London.
In an extensive study, the effect of antiandro-
gens and oestrogen treatment on the level of
circulating dihydrotestosterone and testosterone
was investigated. Patients with histologically
proven prostatic carcinoma are treated by one
of the following treatment modalities according
to a prospective protocol:stilboestrol 1 mg t.d.s.,
cyproterone acetate 100 mg b.d., bilateral orchi-
dectomy or no immediate treatment. Plasma
dihydrotestosterone and testosterone have been
monitored using a sensitive and reliable radio-
immunoassay developed in our laboratory
(Ghanadian et al., 1975, Steroids, 25, 753).
There was a significant correlation between
pre-treatment plasma dihydrotestosterone and
testosterone levels (P < 0 05). However, after
hormonal treatment, such a relationship no
longer existed (P> 0-1) although there was sig-
nificant suppression of both dihydrotestosterone
and testosterone levels. These data suggest a
differential effect on these 2 androgens. Sup-
pression ofplasma testosterone was significantly
less (P < 0 05) in the cyproterone acetate group
than in the stilboestrol or orchidectomy groups.
DISTRIBUTION OF [99mTC]TECHNE-
TIUM-LABELLED LIPOSOMES IN
PATIENTS WITH CANCER. V. J. RICHARD-
SON*, K. JEYASINGHt, R. F. JEWKESt, S. B.
KAYEt, E. S. NEWLANDSt, B. E. RYMAN* and
M. H. N. TATTERSALL$, Departments of *Bio-
cheMistry, tNuclear Medicine and tMedical
Oncology, Charing Cross Hospital and Charing
Cross Hospital Medical School, London.
Liposomes (phospholipid vesicles) have been
proposed as carriers of antitumour drugs in
order to alter the blood clearance, tumour and
marrow localization of the drugs and thereby in-
crease their therapeutic value. y-Camera studies
have shown that 99mTc (technetium) label at-
tached to small anionic liposomes concentrates
in the Walker 256 carcinoma model (Richardson
et al., 1977, Biochem. Soc. Trans., 5, 290). We
have now studied the distribution of 99mTc-
labelled liposomes in 14 patients with advanced
cancer and one patient withpolycythaemia rubra
vera (PRV). Pharmaceutical preparations of
liposomes, 20 or 300 mg of lipid (7:2:1 molar
ratio phosphatidylcholine: cholesterol:phospha-
tidic acid) labelled with 20 mCi of 99mTc, were
injected i.v. Blood clearance and urine excretion
of the label were measured over 24 h, and the
tissue distribution at 24 h was observed using a
whole-body scanner.
In all cases, excluding the patient with PRV,
the major site ofuptake ofthe label was the liver
and spleen. In the patient with PRV, liver and
spleen uptake were greatly reduced and the
majority of the radioactivity was found in sites
corresponding to the marrow.
With the possible exception of one patient
with a hepatoma, there was no evidence of
tumour localization of radioactivity. The inter-
esting results in the patient with PRV mlay re-
flect the altered marrow turnover which occurs
in this condition. Future plans include a study
on larger numbers ofpatients using liposomes of
different sizes and lipid compositions.
DEVELOPMENT OF A RADIOIMMUNO-
ASSAY FOR A RAT SARCOMA-ASSOCI-
ATED SPECIFIC ANTIGEN. V. E. PRESTON
and M. R. PRICE, Cancer Research Campaign
Laboratories, Univ. of Nottingham.
A partially purified, tumour-specific antigen
was isolated from soluble 3 M-KCI extracts of a
transplanted, 3-methylcholanthrene-induced rat
sarcoma Mc7 by immunoadsorption to syngeneic
immnune IgG antibodies immobilized by covalent
linkage to Sepharose 4B (Preston and Price,
1977, Biochem. Soc. Trans., 5, 123). This antigen
preparation was used to prepare a rabbit anti-
serum, which,afterabsorptionwithnormaltissue
extracts and sarcoma Mc4OA cells, displayed
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unique specificity for sarcoma Mc7 cells in in-
direct membrane immunofluorescence tests.
Radioiodinated, immunoadsorbent-purified sar-
coma Mc7 antigen was reacted with this anti-
serum, and labelled immune complexes were
precipitated by addition of an excess of heat-
killed, formaldehyde-fixed Staphylococcus aureus
organisms (which express the Fe-binding com-
ponent, Protein A). A radioimmunoassay for
sarcoma Mc7 antigen was developed by measur-
ing the competitive inhibition of this precipita-
tion reaction by the addition of unlabelled anti-
gen in crude soluble extracts. At the present
stage of development, the assay retains the
capacity to distinguish between extracts of dif-
ferent chemically induced tumours and has been
successfully used to monitor the fractionation of
soluble sarcoma Mc7 extracts.
ENHANCEMENT OF LYMPHOCYTE-
MEDIATED CYTOTOXICITY AFTER
TUMOUR RESECTION IN PATIENTS
WITH COLORECTAL CANCER. P. G. GILL,
C. WALLER and I. McLELLAN, Nuffield Depart-
ments of Medicine and Surgery, Radcliffe In-
firmary, Oxford.
Lymphocyte numbers and function, in 37
patients with colorectal cancer, were compared
with those in 23 healthy control subjects of the
same age range. No significant difference in lym-
phocyte count, numbers of cells forming E
rosettes or bearing surface immunoglobulin,
cell-mediated cytotoxicity or mitotic response to
PHA were found. Six to twelve months after
tumour resection, patients showed a rise in anti-
body and PHA-induced cytotoxicity to levels
significantly higher than those found in age-
matched controls. This rise occurred irrespective
of whether patients had received adjuvant
immunotherapy with C. parvum.
CYTOTOXIC AND PHAGOCYTIC ACTI-
VITY OF HUMAN TUMOUR INFIL-
TRATING MACROPHAGES. B. M. VOSE,
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester.
Adherent cells separated from human tumour
specimens were tested for cytotoxic potential
against antibody-coated human red cells and
against autologous tumour cells in 18 h 51Cr-
release assay. These cells represented 0 2-8 5%
of the cells plated, and had the morphological
appearance ofmacrophages. 64-88% showed up-
take of 1.1 ,um diameter latex particles and 77-
94% pinocytosed neutral-red solution. Lysis of
antibody coated human erythrocytes was de-
termined in 14/15 cases examined with 2 of 20
positive without antiserum. Significantly in-
creased 51Cr release over background was re-
corded in 19/27 tests against autologous tumour
cells using the monolayers aseffectors. Thislatter
cytotoxicity was manifested in the presence of
autologous and allogeneic sera and was also
evident against allogeneic tumour targets. Re-
activity was less frequently determined against
targets from uninvolved lung tissue from pa-
tients with pulmonary neoplasia. Macrophage
cytotoxicity was often associated with T-cell-
mediated anti-tumour cytotoxic activity in the
blood lymphocytes.
IN VIVO FATE OF 125I-LABELLED TU-
MOUR CELLS IN MICE GIVEN ANTI-
BODY AND ARA-C. P. D. E. JONES, F.
GOTCH, G. F. ROWLAND and G. J. O'NEILL,
G. D. Searle Research Labs., High Wycombe,
Bucks., and Nuffteld Dept. Clinical Medicine,
Radcliffe Infirmary, Oxford.
Administration of rabbit anti-EL4-tumour
sera (RaEL4) in conjunction with cytosine
arabinoside (Ara-C) was found to prolong sur-
vival of C57BL/6 mice bearing the syngeneic
EL4 tumour. A synergistic protective effect
against tumour development with antibody and
drug may be obtained by a multiple-treatment
regimen (Davies et al., 1974, Br. J. Cancer, 30,
305). Using 1251-deoxyuridine-labelled tumour
cells and daily whole body measurement of re-
tained radioactivity of individual mice, it is
possible to follow in vivo the fate of the tumour
cells after therapy (Cailson and Terres, 1976, J.
Immunol., 117, 822). Preliminary studies show
that in an allogeneic situation, RaEL4 (0-1-0-2
ml) or Ara-C (1-2 mg) given i.p. or i.v. to CBA
mice 24 h after i.p. injection of 107 labelled EL4
cells, results in the rapid killing of these cells,
whereas rabbit antisera against the C57BL/6
B16 tumour has no effect. The rate of cell death
after RaEL4 and Ara-C in conjunction was
greater than that obtained by either treatment
alone.
This technique allows the analysis and rapid
screening of tumour therapy in vivo with anti-
body and drug, using the mouse as a host to
syn-, allo- and possibly xeno-geneic tumours.
DNA REPAIR SYNTHESIS, FACT OR
ARTIFACT? B. W. Fox, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester.
The measurement of DNA repair synthesis at
different times after treatment, is essential to an
understanding of the relative sensitivity of
tumour lines to DNA-damaging agents. The
density-labelling centrifugation procedure has
been widely used for measuring DNA repair syn-
thesis in the first few hours after treatment.
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However, during investigations over a longer
time, we (Nikaido and Fox, 1976, Chem.
Biol. Interact., 14, 47) observed a pattern of
"repair synthesis" occurring in untreated cells.
This phenomenon has been studied in greater
detail, using a benzoylated-naphthoylated
(BND)-column procedure, which does not re-
quire a density label. The "repair synthesis"
initially observed was found to be due, in part,
to a differential exclusion of DNA precursors by
the cell, possibly at the cell membrane. However,
a further artifact has been uncovered, dependent
on the centrifugation field applied, which has
important implications in the interpretation of
DNA repair synthesis obtained by any of the
current procedures.
INCREASE IN CHROMOSOMAL RADIO-
SENSITIVITY OF CHINESE HAMSTER
CELLS WITH IN VITRO PASSAGE. C. Y.
LYONS, D. SCOTT and J. R. CONNELL, Paterson
Laboratories, Christie Hospital and Holt Radium
Institute, Manchester.
Cells from cancer-prone individuals with a
trisomic chromosome constitution (e.g. Downs
syndrome) have an elevated sensitivity toX-ray-
induced chromosome aberrations (Sasaki et al.,
1970, Mutation Res., 10, 617). The sensitivity
of a trisomic Chinese hamster cell line (passage
40) to X-ray-induced chromosome damage was
found to be twice that of the diploid line (pas-
sage 16) fromwhichitarosespontaneously. A line
carrying a simple inversion (passage 9) was of
similar sensitivity to the diploid. Further
experiments suggest, however, that the differ-
ence in radiosensitivity is not related to the
karyotypic differences, but to age in culture,
since the diploid cells were found to increase in
sensitivity between passage 16 and 47. Cells may
lose their repair capacities with increasing in
vitro culturing.
REGRESSION PATTERN ANALYSIS
FOR THE CELLULAR CHEMOSENSI-
TIVITY OF HUMAN MULTIPLE MYE-
LOMA. G. F. BRUNTON, T. E. WHELDON and
A. H. W. NIAS, Glasgow Institute of Radiothera-
peutics and Oncology, WesternInfirmary, Glasgow.
The kinetics of growth and regression during
non-cycle-specific chemotherapy of human IgG
multiple myeloma using melphalan, may be in-
terpreted using a mathematical model which
allows identification of the parameter of cellular
chemosensitivity, Do, for an individual patient.
Knowledge of these paramneters may be used
to predict tumour response, not only to the con-
tinued application of the treatment schedule
chosen originally, but also to any other schedule
using the same agent.
For 11 published cases (Sullivan and Salmon,
1972, J. Clin. Invest., 51, 1697) the mean Do was
found to be 77-6 mg, with a range of 25-4-198
mg, reflecting an intrinsic variability in chemo-
sensitivity to melphalan at the cellular level, and
emphasizing the necessity of individually orien-
tated schedule design. Computer simulation of
individual response to alternative schedules,
using Do values estimated early in an arbitrarily
chosen schedule, may assist in rationalizing the
therapy of this disease.
FLUOROCHROMASIA AND FLUORES-
CENCE POLARIZATION IN LYMPHOID
CELLS. A. W. PREECE, P. A. LIGHT and P.
BALDING, Oncology Research Laboratories, Radio-
therapy Centre, Bristol.
The SCM test for malignant disease utilizes
the change in polarization value offluorescein to
demonstrate lymphocyte response to PHA or
tumour basic protein (TBP).
The kinetics of fluorochromasia in a range of
lymphoid cells, including human lymphocytes,
is such that there is a rapid decrease in polariza-
tion over 10-20 minutes, related to the rate of
accumulation of intracellular fluorescein. The
presence of PHA or TBP does not appear to
alter the polarization value, but may have an
effect on the rate ofhydrolysis and accumulation
of fluorescein.
Data for a group of healthy controls and can-
cer patients show no significant difference in the
curves of P value against time.
CELLPARTITION: OPTIMUM SYSTEMS
FOR DETECTION OF SURFACE CHAN-
GES. J. P. DICKINSON and C. M. BALLARD,
Y.C.R.C. Laboratories, Univ. Dept. of Radio-
therapy, Cookridge Hospital, Leeds.
Following on the partial success of cell parti-
tion as an attractive alternative to the MEM
test for lymphocyte sensitization (Smith and
Dickinson, 1976, Lancet, ii) detailed study of
the partition phenomenon has been made, in
order to optimize conditions for routine mea-
surement of cell-surface-charge changes.
For a variety ofcells modifiedinsurfacecharge
by digestion with neuraminidase or trypsin, or
treated with maleic anhydride, changes in parti-
tion coefficient correlate strongly with changes
in electrophoretic mobility: theoretically each is
dependent on the surface-charge density.
Optimum phase systems for observation of
increases or decreases in surface charge ofhuman
lymphocytes, leucocytes and erythrocytes,
guinea-pig macrophages and tanned sheep ery-
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throcytes have been defined in terms of polymer
and electrolyte concentration.
As a corollary, study of the transfacial poten-
tial difference (AV) shows that, as predicted by
theory, ln (partition coefficient) oc AV. Increas-
ing PEG concentration increases AV; increasing
NaCl beyond 30 mM reduces AV virtually to
zero. Polymer-alone systems exhibit a definite
AV which is greatly increased by small concen-
trations (< 10 mM) but gradually discharged by
increasing concentrations, of phosphate buffer.
ORGAN DISTRIBUTION OF NATURAL
CYTOTOXICITY IN THE RAT. M. R,
POTTER and M. MOORE, Immunology Division.
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester.
The natural (spontaneous) cytotoxicity (NC)
of cell populations from different lymphoid
organs of the rat were examined, using a human
myeloid cell line (K562) and a rat fibrosarcoma
cell line (Mc4O) as target cells. Rat blood and
spleen lymphoid-cell populations gave high cyto-
toxicity against K562, while lymphnode cells
and marrow cells gave low levels ofcytotoxicity,
and thymus cells virtually no activity. Addition
of thymus or lymphnode cells to spleen effector
cells did not suppress the high cytotoxicity of
spleen cells. A similar organ distribution of re-
activity was seen against Mc4O cells, but the
levels of cytotoxicity were much lower than for
K562.
A strain difference was monitored in the levels
ofnatural cytotoxicity and cell populations from
inbred Wistar rats consistently gave higher
activity on a cell-to-cell basis than the corres-
ponding population from PVG/c rats. Natural
cytotoxicity was not removed when spleen-cell
populations were depleted of cells adhering to
nylon-fibre columns or plastic surfaces, or de-
pleted of cells ingesting carbonyl iron. In agree-
ment with other studies using human and
animal lymphoid cells, the natural killer cell in
this system was found to be non-adherent and
non-phagocytic and its distribution did not
correspond to the established organ distribution
of T or B lymphocytes.
NATURAL CELL-MEDIATED IMMU-
NITY: REACTIVITY AGAINST MYCO-
PLASMA-INFECTED CELLS. C. G.
BROOKS*, R. C. REESt and R. H. LEACH$,
*Cancer Research Campaign Laboratories, Univ.
of Nottingham, tDept. of Virology, Univ. of
Sheffield Medical School, JMycoplasma Reference
Laboratory, Norwich.
We have found that infection of tumour cells
with certain mycoplasma species causes a large
increase in their susceptibility to the cytotoxic
effects of natural killer (NK) cells. Of 3 myco-
plasma species tested, two have this property-
M. arginini and M. hyorhinis-while a third,
M. orale, has been found to be negative. The
NK-cell reactivity against mycoplasma-infected
tumour cells crosses both strain and species
barriers. For example, lymphnode cells (LNC)
from syngeneic rats, allogeneic rats, mice and
rabbits are reactive against mycoplasma-in-
fected rat tumour cells. Natural immunization
by mycoplasma or bacterial infection is not
responsible for this reactivity, as LNC from
mycoplasma-free and germ-free rats were as
reactive as LNC from conventionally housed
rats. Furthermore, spleen cells from nude mice
were strongly reactive, indicating that the
effector cell is non-T. These findings suggest that
the elevated NK-cell reactivity often observed
against in vitro-grown target cells may some-
times be caused by mycoplasma infection, and
indicates that mycoplasma infection somehow
increases target-cell sensitivity to NK cells.
RESPONSE OF MURINE THYMUS
CELLS TO DEVELOPMENT OF A
TRANSPLANTABLE TUMOUR. P. A.
LIGHT, A. W. PREECE and R. ASPINALL, On-
cology Research Laboratories, Radiotherapy
Centre, Bristol.
Alterations in the properties of murine thy-
mocytes during development ofa transplantable
tumour (NK/Lymphoma) have been detected
by measurements of migration inhibition of
thymocytes. It was found that marked inhibi-
tion ofmigration from capillary tubes ofthymo-
cytes from tumour-bearing animals occurred
when autologous tumour-cell fragments were
present in the medium surrounding the capillary
tubes. Such migration inhibition was observed
with thymocytes from animals in whom the
tumour had been transplanted only 6 h earlier.
By 24 h after tumour transplantation, inhibition
had risen to 65%, and by Day 5 was 95%. Simi-
lar effects were observed when syngeneic lym-
phoma-cell fragments were tested against thy-
mocytes from tumour bearers, although the
actual inhibition values were slightly lower.
Thymocytes from normal animals were tested
in the same migration assay system against
membrane fragments prepared from lymphoma
cells from various stages of growth. In no
instance was any migration inhibition observed
in these controls.
TRANSPLANTATION OF CANINE
LYMPHOSARCOMA TO NUDE MICE.
D. R. MORGAN, D. E. ONIONs and L. N. OWEN,
Dept. of Clinical Veterinary Medicine, Univ.
of Cambridge.
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The successful transplantation of caninie
osteosarcoma, mammary carcinoma and mela-
noma to nude mice has been previously re-
ported (Oughton and Owen, 1974, Res. Vet. Sci.,
17, 414; Morgan, 1977, Br. J. Cancer, 36, 427).
Attempts to transplant both human and canine
lymphosarcoma have rarely been successful, al-
though bovine lymphosarcoma has been trans-
planted to nude inice following whole-body X-
irradiation (Irvin et al., 1977, Res. Vet. Sc., 22,
53). In our experiments cell suspensions oflymph
node from each of 11 dogs histologically diag-
nosed as multicentric lymphosarcoma were in-
jected into outbred nude mice. In one case the
recipient mice were pretreated with 300-500 rad
of whole-body X-irradiation. Tumours did not
grow in non-irradiated mice, but all X-irradiated
mice developed tumours within 4 weeks. The
tumour was readily passaged in vivo and from
the second passage tumours grew in non-irra-
diated mice as rapidly as in mice given whole-
body X-irradiation. S.c. tumour growth was
diffuse and infiltrating, and injection of 5 x 107
cells produced 5 g oflymphosarcoma tissue with-
in 6 weeks. The tumour was composed of closely
packed lymphoid cells with some lymphoblastic
types, and mitotic figures were common.
Metastases were frequent, affecting the axillary
lymph nodes, lungs, kidney and heart.
THE ADHESION OF CELLS TO 3-DI-
MENSIONAL COLLAGEN LATTICES.
S. L. ScHoR* and T. D. ALLENt, *C.R.C. Depart-
ment of Medical Oncology, tDept. of Ultrastruc-
ture, Christie Hospital, Manchester.
We have ineasured the kinetics ofcell adhesion
to both plastic tissue-cullture dishes and 3-
dimensional collagen lattices. The cells exam-
ined in this initial study (24 types) include
normal, transformed and tumour cells of both
epithelial and mesenchymal origin. Cells were
removed from the surfaces of plastic tissue-
culture dishes by a 20 min incubation in EGTA
(2 mM) and trypsin (0-05%) and a cell suspension
(1 x 105 cells/ml) prepared in growth medium
supplemented with 10% foetal calf serum. 1 ml
of cell suspension was then added to 35 mm
plastic dishes, with or without a collagen sub-
stratum, and the kinetics of cell adhesion de-
termined by counting the number of cells re-
coveredin the medium aftergentle washingofthe
dishes at various times. The cells examined in
this manner fall into 3 distinct groups as defined
by their relative kinetics of adhesion to plastic
and collagen (the data are expressed as % of ini-
tial cells adherent after 2 h): the cells may
(a) adhere at an equal rate and extent to both
plastic and collagen ( > 80%), (b) adhere faster
to plastic (> 80%) than to collagen (< 20%), or
(c) adhere faster to collagen ( > 80%) than to
plastic ( < 20%).
Differences in overall cell inorphology, as well
as surface details, were observed with the SEM
between cells grown on plastic and collagen.
These morphological and kinetic data form the
basis for ongoing work designed to examine the
mechanism ofcell adhesion to collagen, especially
possible differences which may exist between
cell types.
GLYCOPROTEINS AND GLYCOSAMI-
NOGLYCANS OF CULTURED HUMAN
SKIN FIBROBLASTS. N. GASIUNAS, J. T.
GALLAGHER and S. SCHOR, C.R.C. Department
of Medical Oncology, Christie Hospital, Man-
chester.
Monolayers of adult human skin fibroblasts
grown on plastic surfaces or collagen gels were
incubated for 48 h with 3H-glucosamine and
Na235SO4. A trypsin (0-05% w/v)/EGTA (2 mM)
extract of cells on plastic, presumed to contain
cell-surface and intercellular macromolecules,
was analysed by gradient elution from DEAE-
cellulose. Four 3H-labelled peaks were resolved,
but only two of these were labelled 35S-sulphate.
The non-sulphated components were hyaluronic
acidandacidicglycoproteins; thedoubly-labelled
peaks were heparin sulphate (HS)/(main com-
ponent) and chondroitin sulphate-B (CS-B).
Cells grown on collagen gels were not detached
by trypsin/EGTA, but this solution mobilized
labelled materials qualitatively similarly tothose
on plastic. but with a significant shift in the sul-
phated glycosaininoglycans to predominantly
CS-B. The gel was then dissolved with collagen-
ase, which released adhering cells and cells
which had migrated into the gel network. The
collagenate was also enriched in CS-B, and in
addition showed a greatly elevated 3H-label in a
neutral glycoprotein. Thus, modification in the
pattern of "matrix" synthesis by cells in vitro
can be mediated through an interaction between
cells and their environment.
SYNTHESIS AND RELEASE OF SPECI-
FIC PROTEIN PRODUCTS BY HUMAN
MAMMARY TUMOUR CELLS IN VITRO.
R. J. GRIEVE, K. L. WOODS, D. H. COVE, S. C.
H. SMITH, J. LEONARD* and A. HOWELL, Depts.
of Medicine and Experimental Pathology, Univ.
of Birmingham, and *The Birmingham and Mid-
land Hospital for Women, Birmingham 11.
We have found that lactalbumin, oc subunit
of glycoprotein hormones and carcinoembryonic
antigen are elevated in the sera of 12%, 8% and
16% of patients with operable breast cancer
(Stages I and II). The same proteins have been
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identified in the cytosols of 35%, 42% and 70%
of primary mammary carcinomas. If these pro-
teins are to prove of value as tumour markers,
information is needed on the control of their
synthesis and release. All 3 proteins are produced
by the human mammary carcinoma line MCF-7,
and we have studied their regulation in vitro.
Sodium butyrate increases a subunit production
by a factor of 264 and lactalbumin production
by a factor of 40. Synthesis and release of a
subunit is increased by phosphodiesterase in-
hibitors, but unaffected by LHRH and TRH.
COHORT STUDY OF OVARIAN CANCER
CASES. D. J. HOLE and C. R. GILLIS, Carzer
Surveillance Unit, Ruchill Hospital, Glasgow.
Aspects of aetiology, management and sur-
vival in ovarian cancer have been examined in
a prospective study ofall cases first diagnosed in
1974 and resident in the geographical area de-
fined as the West of Scotland (population 3
million). Ovarian cancer, with an overall inci-
dence of 11 cases per 105 females, exhibits vary-
ing age-specific rates and aetiological factors,
when divided into distinct tumour types. Germ-
cell tumours occurpredominantly at the younger
ages, while mucinous tumours are related speci-
fically to zero and low parity. Mucinous tumours
also tend to present at the earlier stages, and are
more amenable to complete surgical removal,
whereas undifferentiated tumours prove to be
the most difficult to treat.
Study of the management of ovarian cancers
shows that for early disease cases, complete re-
moval is effected in 60% of cases and this is
usually combined with radiotherapy or, alter-
natively, no additional treatment is given. In-
complete removal is most commonly combined
with chemotherapy. For extensive disease, 67%
had no surgical intervention and of these 52%
received chemotherapy and 43% received no
other treatment.
The FIGO staging of cases with malignant
cells in the fluid as stage Ic, is questioned, as
they have a 2-year survival of22%, which is only
marginally better than that for Stages III and
IV. The amount of tumour removed is the best
single factor associated with a good survival,
whereas age, pathology and the different me-
thods of treatment showed little correlation. A
baseline has now been established for compari-
son with results for later years and a methodo-
logical study has been made on quality-of-life
parameters.
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